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by
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ABSTRACT
African Americans are twice as likely as non-Hispanic Whites to develop Alzheimer’s Disease.
Current approaches to studying Alzheimer’s disease do not include a sufficient minority population
needed to understand the nature of this disparity. Evidence from epidemiological and cerebrospinal fluid
biomarker studies suggests that African Americans do indeed represent a unique phenotype of
Alzheimer’s disease, partly driven by an elevated presence of risk factors. These risk factors include, but
are not limited to an elevated presence of vascular disease which can manifest in the brain in the form of
White Matter Hyperintensities (WMH). Functional magnetic resonance imaging is a method of detecting
brain activity, and has been used to detect neurological changes within Alzheimer’s Disease in the form
of functional connectivity (FC). FC is a measure of the correlation of activity between brain regions. In
our first aim, we examined connectivity between a well-studied network, the default mode network and
how race modifies the relationship between AD biomarkers and connectivity, and whether WMH in this
network accounts for these racial differences. We found that race does modify the relationship between

CSF t-Tau, Aβ42, and cognitive performance between the midline core and dorsomedial subsystems, but
that WMH did not account for these differences. In our second aim, we analyzed connectivity between
regions not typically associated with AD including the anterior putamen, pre and post central gyri, and
superior and middle frontal gyri. We found that, independent of race, anterior putamen to pre and post
central gyri increased as CSF Aβ42 decreased, but the connectivity decreased as regional WMH volume
increased. Within African Americans, connectivity between the middle and superior frontal connectivity
decreased as CSF Aβ42 decreased, and as regional WMH volume increased. This work further
characterizes the AA dementia profile, and provides novel regions of exploration that may be affected by
AD. Furthermore, we provide neurological support for the claim that in studies of individuals with
Alzheimer’s disease, race should be considered as an important factor of interest in analyses.

INDEX WORDS: Alzheimer’s Disease, Functional neuroimaging, Disparities, Magnetic resonance
imaging, cerebellum, basal ganglia, Default Mode Network
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1.1

INTRODUCTION

Purpose of the Study
African Americans are twice as likely as Caucasians to develop Alzheimer’s disease (AD) in their

lifetime1. While hypotheses exist to explain this disparity, there is no known mechanism that fully
accounts for it2. This lack of knowledge may be attributable to the fact that AD studies typically contain
data collected from upper-middle class NHWs (Non-Hispanic Whites) with lifestyle and genetic
backgrounds dissimilar to those of African Americans (AAs)3. In order to determine the nature of the
differences between Caucasians and African Americans with dementia, we must create models that
consider the multifaceted concept of race.
One method of modeling neurological changes in dementia is magnetic resonance imaging
(MRI)4. Functional neuroimaging (fMRI) can identify changes in brain activity that supplement current
AD models5. Disease related fMRI changes correlate with AD biomarkers including tau deposition6,
amyloid levels7, brain atrophy8, and cognitive performance9. The proposed study seeks to identify the
unique characteristics of the functional imaging profile of African Americans and determine whether
ischemic neurological damages in the form of white matter hyperintensities account for any observed
disparities.
1.2

A Short Discussion of Race
Before delving into a discussion of the African American phenotype in the context of

Alzheimer’s Disease, we must first operationalize the concept of race, and how we propose to study it in
this body of work. For the purposes of this study, race is a self-reported measure of belonging to a
specific ethno-cultural group, in this case either NHW or African American. Although it may seem to be
more biologically viable to include only genetic information to determine race, it would exclude relevant
lifestyle and cultural factors linked to Alzheimer’s disease such as diet, activity levels, and access to
healthcare10–13. To understand the nature of racial disparities in dementia we will include race as a
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variable in our models, and then unpack factors under the umbrella of race such as genetic risk factors,
comorbidities, and socio-economic status (SES) to determine the extent to which these factors account for
that variability attributed to race.
1.3

Alzheimer’s Disease & Health Disparities
Over 5 million Americans currently live with Alzheimer’s disease. It is the sixth leading cause of

death in individuals over 651. Individuals with Alzheimer’s disease will eventually succumb to its effects,
but usually not without a gradual decline in daily function. This places a tremendous burden not only on
the individuals with AD, but caregivers and health professionals that must provide support for patients
during the diseased period of their lives14. Despite these facts, it remains as the only disease within the top
10 leading causes of death to have no concrete method to slow, prevent or, cure the disease1.
1.3.1

Racial disparities in AD
African Americans are twice as likely to develop AD within their lifetime as are NHWs 2.

Additionally, unique ethnoracial AD profiles have been identified for CSF 2,15, blood proteomic16,
genetic17, and lifestyle risk factors18. However, the overwhelming majority of data used to create
diagnostic and progression models of AD are from NHW populations19. Recruitment and study
participation bias likely results from an interplay between convenient sampling20, and a lack of active
networking with diverse populations that may be less likely to seek healthcare at early stages of AD21, and
exhibit more mistrust towards the scientific and medical community22. Analyses that explicitly consider
race as a variable of interest may not only enable us to uncover the nature of dementia disparities, but
indicate to the populations of interest that everyone’s unique life experiences and circumstances are
valued and important to the scientific community, which could increase research participation of minority
groups23.
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1.4

Etiology and Clinical Diagnosis of Alzheimer’s disease
While we do not fully understand the causes of and risk factors for AD, the disease pathology is

fairly well defined. Alzheimer’s disease is characterized by the presence of two cellular abnormalities,
amyloid beta plaques, and neurofibrillary (tau) tangles24. A definitive diagnosis of AD can only be given
after autopsy of the brain25. The presence of neuro-fibrillary tau tangles (NFTs) and Amyloid-beta (Aβ42)
plaques serves the basis for a post mortem diagnosis of AD, but this diagnosis is obviously not relevant
for those living with AD. In the clinic, AD dementia is diagnosed using a multi-faceted approach. A
diagnosis of Alzheimer’s disease usually comes after a consensus among imaging results, cognitive
testing, clinical interviews, and, rarely, cerebral spinal fluid biomarkers (tau and Aβ42)26–28.
Tau and Aβ42 can be detected in cerebrospinal fluid (CSF), and can aid in the diagnosis of AD, in
that if they are present at pathological levels it would support a diagnosis of AD dementia versus another
type of dementia29–31. Accumulation of Aβ42 is normal in the aging brain, but the molecular composition
of plaques in AD is unique24. The Amyloid hypothesis implicates the accumulation of Aβ42 as the impetus
for AD32: i.e., Aβ42 plaques accumulate, which then starts a host of cellular inflammatory responses that
lead to NFTs, which then leads to neuronal degradation and atrophy33. Although it may seem that the
presence of Aβ42 is pathogenic, we do not know the mechanism by which it is toxic34. Despite its
widespread acceptance over the last decade, many clinical trials that decrease Aβ42 accumulation have
failed, discrediting the amyloid hypothesis32. While the proposed study does not directly probe the
cellular interactions of Aβ42, better characterizing the diverse population of individuals with AD may
enable researchers to identify similarities in brain pathology that can aid in the refinement of the amyloid
hypothesis.
Despite the unanswered questions about Aβ42 toxicity, there is much evidence that tau
accumulation and migration across the brain has deleterious effects35. In its normal state, tau is a
microtubule-associated protein whose function is to stabilize microtubules that maintain cell polarity and
axonal transport36. In AD, tau is typically hyperphosphorylated, which may block necessary microtubule
binding sites36. When tau is present, but does not serve to stabilize microtubules, the microtubules
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disassemble, and tau accumulates in paired helical filaments, forming the classic neurofibrillary tangles
(NFTs)36. Without the microtubule structure, axonal transport ceases, and the neuron eventually dies.
Increased tau levels are detectable in the CSF, and CSF t-Tau serves as a better marker of disease
progression than Aβ42, as it more closely correlates with cognition31,37,38.
From a cognitive standpoint, memory impairment is the hallmark cognitive sign of Alzheimer’s
disease, and is typically correlated with CSF biomarkers of AD and hippocampal atrophy39,40. Short term
memory deficits are commonly reported in individuals that receive a diagnosis of Alzheimer’s Disease. In
clinical diagnosis, memory complaints that impair with daily function are often sufficient to receive a
diagnosis of AD40. However, an individual can present with a mixed cognitive profile, with visuospatial
and executive function deficits as opposed to only memory complaints25–27. In fact, African Americans
are more likely to exhibit non-amnestic cognitive profiles than NHWs42.
Much of the diagnostic process of AD involves ruling out other causes of dementia including
stroke, vascular dementia, Parkinson’s disease, geriatric depression, etc. While CSF measures and PET
images have greater specificity for AD, combined with magnetic resonance imaging (MRI), they are
much more powerful, and MRI has been cited as more stable indicator of neuronal loss than CSF
markers44.
1.4.1

Racial Disparities in diagnostic models of AD
In multiple cohorts, African Americans have lower CSF total tau than NHWs15,45 despite similar

levels of Aβ42 and similar cognitive function. This may suggest that African Americans exhibit
pathological processes after amyloid deposition distinct from NHWs. Additional considerations include
genetic risk factors unique to race. APOE e4 and the ABCA7 alleles occur at increased rates in AAs, and
confer different risks across races46. ABCA7 confers a greater risk for AD in AAs, and is present at higher
rates in this population17,47. Presence of the APOE e4 allele has differential effects on functional
connectivity according to race48. We will carefully consider these risk genes in our analyses to determine
whether their presence explains the racial differences we may observe in connectivity to biomarker
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relationships. Furthering our understanding of the observed differential tau and genetic burden in the
context of additional AD biomarkers may broaden our understanding of Alzheimer’s disease, and allow
current models to be more generalizable.
In general, African Americans may exhibit a distinct cognitive profile in the presence of AD.
African Americans may be less likely to exhibit amnestic profiles (memory impairment), and thus more
likely to exhibit dysexecutive syndromes and visual spatial impairment. Cognitive decline in the presence
of AD may occur at a slower rate in African Americans than NHWs49, 29. This distinct cognitive profile
may contribute to the under-diagnosis of AD in African Americans, as AD diagnosis is biased towards
memory complaints and rapid decline12. However, standard clinical assessments typically underestimate
daily function and overestimate cognitive impairment in African Americans50. While the cognitive profile
of African Americans with AD is well-characterized, we still do not know the cause of the cognitive
disparities. The measurement tools themselves may not possess the nuanced cultural relevance required to
address cognitive impairment in minority populations, as they were developed and validated in a
homogenous Non-Hispanic White population 51,52,53. Given the inaccuracies in cognitive assessment
within African Americans, when comparing the relationship between cognition and other AD biomarkers,
we must consider the underlying racial differences and normalize scores appropriately in statistical
analyses54–56.
1.5

Functional Neuroimaging
Neuronal dysfunction can be indirectly measured by changes in blood flow to regions of the brain

using the Blood Oxygen Level Dependent (BOLD) signal57. This type of imaging, known as functional
magnetic resonance imaging (fMRI), can detect functional changes in the framework and meaning of
“functional networks”. Structural changes occur well after cognitive changes can be detected in the
trajectory of AD. Memory impairment usually begins before the hippocampus has noticeable atrophy,
suggesting that neuronal dysfunctional precedes atrophy58. Figure 1 shows the progression of Alzheimer’s
disease, and when specific biomarker changes occur in the context of symptom emergence. This figure
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indicates the utility of resting state (rs)-fMRI over structural MRI to detect differences between healthy
aging brains and those that show signs of dementia, and can be utilized throughout the disease spectrum.
Of note, this figure shows the emergence of tau markers after rs-fMRI changes begin. Because resting
state measures may not correlate with tau until an individual has reached a particular threshold of
amyloid, we will analyze tau and resting measures in individuals who have a clinically significant burden
of amyloid. The following sections will discuss the what is known about the functional profile of
Alzheimer’s disease.

Figure 1 Timecourse from Preclinical to Clinical AD: Pathophysiology and Imaging. Taken from
Sheline, et. al., 2013.
1.5.1

Default Mode Network in Alzheimer’s Disease
Regions of the brain that exhibit highly correlated (or connected) BOLD single activity are

known as “functional networks”. The default mode network (DMN) is perhaps the most commonly
studied functional network, particularly in dementia59. Typically, regions, or nodes, of the default mode
network include the ventromedial prefrontal cortex, the precuneus, posterior cingulate, and the inferior
parietal lobule60,61, but others have divided the DMN into distinct functional subsystems62, and others
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include the hippocampus as part of this network63. In this work, we focus on connectivity measures
between nodes of the DMN subnetworks.
Within Alzheimer’s disease, lower connectivity between DMN nodes is the most commonly
reported fMRI finding58,64. Within AD, connectivity typically decreases over time, and is lower among all
regions of the DMN65. DMN connectivity also correlates with other AD biomarkers such as CSF Aβ42
levels, and hippocampal volumes such that as disease burden indicated by these biomarkers increases,
DMN connectivity decreases45,66. However, DMN results are not consistent across all studies. Some
studies have identified a spike in connectivity in the early stages of the disease, during a stage known as
mild cognitive impairment (MCI), and then a gradual decline67,68. Some studies only report a decrease in
connectivity between anterior and posterior DMN regions, and others indicate widespread DMN
changes59,63,65,69. The reasons for these discrepancies may be methodological, but it is also possible that
essential demographic variables, such as race, were not considered in the analysis. Because African
Americans exhibit a unique phenotype of AD, and functional connectivity of the DMN is a potential a
biomarker AD, it is important that racial differences in functional connectivity be explored. One aim of
this work is to explore the correlates of DMN connectivity in individuals with Alzheimer’s disease, and
examine how race may modify connectivity relationships to other biomarkers.
1.5.2

Racial Disparities in Functional Connectivity
Functional connectivity has not been adequately explored in the context of racial differences.

Most studies that investigate functional connectivity in African Americans either do not report the racial
makeup of their sample10, or recruit diverse samples, but do not include race as a factor of interest in
statistical models70,71, or only recruit African Americans72,73,74. We are by no means suggesting that these
approaches are flawed, but to point out the literature examining racial disparities in functional
connectivity profiles is essentially non-existent. Indeed, outright study of racial disparities must be
thoughtfully conducted as it would be easy to utilize these findings to support discriminatory ideologies.
However, if we are to understand the nature of racial disparities in Alzheimer’s disease, explicitly
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exploring racial differences is crucial. Because of the gap in the literature on this topic, we have looked to
studies of racial disparities using other AD biomarkers to inform our hypotheses for this work, and we
hope that these studies begin to fill this hole.
1.6

The Putamen in Alzheimer’s Disease
While much of the research in dementia has centered around the DMN, there is evidence that

regions outside the DMN may be effected by AD pathology, as far as 10 years out from symptom onset75.
The putamen is region that is susceptible to both vascular disease76,77 and the effects of AD75. This
phenomenon has been observed in studies of pathology78, positron emission tomography (PET)79, and
structural MRI75, with little evidence from functional MRI in AD. Unlike the DMN, the putamen and its
network nodes are responsible for cognitive performance outside memory domains, including executive
functions, motor coordination, language processing, and visual spatial function80,81. Many individuals,
including a larger percentage within the AA population50, experience cognitive impairment in these
domains in addition to memory41. Because the putamen is involved in these non-memory functions, but
does exhibit vulnerability to AD, examining this region and its functional networks could provide a novel
therapeutic target for interventions. However, we must first establish whether connectivity metrics within
putamen networks correlate with known AD biomarkers.
Functional putamen networks are fairly well defined in the motor-disease literature82,83.
Tractography and functional connectivity studies have identified the caudate, parts of the thalamus,
superior frontal gyrus, middle frontal gyrus, and pre-and post-central gyri as regions most structurally and
functionally connected to the putamen84,83. The anterior putamen has clear functional divisions on the
anterior-posterior axis; the anterior putamen (APu) is classically viewed as a an associative region while
the posterior putamen supports motor function 85. The APu appears to be more affected by AD than its
posterior counterpart in structural MRI86,87,88 and atrophy of the APu better correlates with cognitive
decline75,89. In this work, we investigate putaminal, specifically APu connectivity to further our
understanding of the role of the putamen in AD. Additionally, because the putamen is vulnerable to both
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AD and vascular disease, we will investigate the role of white matter hyperintensities (WMH) in putamen
connectivity.
1.7

White Matter Hyperintensities
White Matter Hyperintensities are a significant risk factor for subsequent development of dementia,

and are related to a number of lifestyle and biological factors90. White Matter Hyperintensities (WMHs)
are damaged areas of periventricular and subcortical white matter that appear hyperintense on T2
weighted and Fluid Attenuated Inversion Recovery (FLAIR) scans91. Common neuropathological
explanations of WMH include demyelination and axonal loss, endothelial dysfunction, and glial
atrophy91. Their prevalence is variable in aging populations, and represent a risk factor for a host of
neurological and cognitive complaints later in life such as an elevated risk of stroke or developing mild
cognitive impairment92. Despite the prevalence of WMH in dementia, they are not specific to Alzheimer’s
Disease92,93. Although WMH are a risk factor for AD, their absence does not rule out AD, and they can
occur without amyloid and tau pathology94. Lifestyle and biological factors can affect the presence of
WMHs such that individuals who smoke95, have diabetes96, or cardiovascular disease39 are at an increased
risk of developing WMHs.
White matter hyperintensities (WMH) are a common finding in individuals with Alzheimer’s
disease (AD), but their etiologic role in AD is not well understood. There is an increasing debate as to
where amyloid and tau can cause WMH, or whether amyloid and WMH have a synergistic
relationship98,99. Individuals with WMH typically have cognitive profiles different than those with “pure
AD”, the former causing generalized, but less severe, cognitive deficits, and the latter causing memory
impairment 100. However, recent evidence indicates that WMH could emerge independently of vascular
disease and arise as a direct result of dementia, as an inflammatory response to amyloid beta
plaques101,102. It is likely that the two pathologies have a synergistic relationship such that presence of
WMH can increase vulnerability to AD pathology, particularly Aβ42 plaques. In this work, we will
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examine WMH and their correlation with CSF levels of tau and amyloid to determine whether the two
AD biomarkers are related, and whether race modifies this relationship.
Some studies suggest that location of WMH determines whether they are AD related, or a result of
vascular disease. WMH seem to have greater posterior involvement in individuals with AD, particularly
in the parietal lobe98,103. Multiple studies have identified that the presence and volume of WMHs is greater
in individuals with MCI and AD92,98,104. Some purport that WMHs provide a secondary neuronal insult
that, in the presence of amyloid deposition, is necessary for the generation of AD105. Others cite the
importance of the location of WMHs as indicative of disease processes, with AD particularly associated
with posterior periventricular WMHs caused by tau41,42,102. In this work, we will examine the regional
volume of WMH to determine if WMH in particular brain regions correlate with levels of CSF tau and
amyloid which would support some type of causal mechanism between AD and WMH, and whether race
modifies these relationships.
WMH can influence functional connectivity measures. WMH along tracts that are between grey
matter regions of interest (ROIs) can influence connectivity, with connectivity decreasing as internodal
WMH burden increases106,107. This is likely a result of the decline in neurovascular coupling that occurs in
the presence of general vascular disease, and, more specifically, ischemic damage, of which WMH are a
symptom108. We have chosen to focus on regions that are typically associated with AD (DMN), and
regions vulnerable to both AD and vascular disease (putamen networks) to determine if the connectivity
measures among these regions more strongly correlates with AD biomarkers or WMH to determine the
nature of the functional connectivity alterations that we may identify.
1.7.1

Racial Disparities in White Matter Hyperintensities
WMH volume better predicts cognitive outcomes than hippocampal volumes in African Americans

with dementia and Alzheimer’s disease49,109–112. One explanation of this disparity is that African
Americans are more likely than NHWs to exhibit mixed pathology in the presence of AD, particularly
evidence of cardiovascular disease113, and that it is consideration of these contributing co-morbidities in
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the presence of AD pathology that predicts cognitive outcomes in this population114. Any functional
connectivity differences that we identify between races may be attributable to differences between
regional distribution of WMHs, as we have identified racial differences in the correlates of WMHs 115,116.
To date, no studies investigating differences between regional WMH volumes and functional connectivity
in the context of race have been published.
1.8

Dissertation Aims
African Americans have a disproportionately high concentration of lifestyle risk factors, and are

more likely to show mixed AD pathology when compared to NHWs. As previously mentioned, African
Americans have higher rates of type-2 diabetes, that may have its roots in both genetic and lifestyle
factors117. They also have higher rates of vascular disease, including atherosclerosis and peripheral
vascular disease118,119. Both type-2 diabetes and vascular disease are risk factors for Alzheimer’s
disease120–122. African Americans have a disproportionately high level of environmental and lifetime
stressors, which contribute to over poorer brain health12. African Americans, on average, experience more
perceived stress than age and education matched NHWs, and these stressful life events have a greater
negative impact on cognition123,124. African Americans are more likely to have a lower socioeconomic
status, which usually carries with it substandard housing, low education, and unemployment, all of which
are individual risk factors Alzheimer’s disease125–129. It is difficult to delineate lifestyle from genetic
factors when individuals with similar genetic backgrounds have similar life experiences and
surroundings130. However, in our analyses we will include as many of these relevant potential mediators
as possible, to uncover biological mechanisms that may explain racial differences.
African Americans have specific genetic risk factors for AD. The APOE e4 allele is more
common in African Americans, and only one copy of the e4 variant is necessary to confer a greater AD
risk for African Americans, unlike other races such as NHWs, in which two copies of the e4 allele are
necessary to increase the risk of AD131,132. This risk is not purely genetic, as studies with African Yoruba
tribes show that two copies of the allele are required to increase the risk of developing dementia133. The
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ABCa7 gene is also associated with increased risk of developing Alzheimer’s disease within African
Americans, but because the presence of the risk allele is highly collinear with race, its effect can only be
analyzed within race134,17. Most of the studies that focus on these risk alleles logistically correlate the
presence or absence of AD with presence or absence of one or two risk alleles. While useful in
determining the whether a gene poses a risk, little is known about the disease mechanism behind the risk
alleles and the subsequent effect on brain pathology. In our regression models, we will include the
presence of APOE e4 as a factor, to determine if it is related to structural and functional neuroimaging
measures.
The current set of diagnostic criteria may not be applicable to the broad population of individuals
with AD. Most of the current models of Alzheimer’s disease, and associated diagnostic cutoffs, have been
generated in a primarily upper-middle class Caucasian population19,135–137. In order to expand current
models of AD to a wider population, we must recruit individuals from more diverse backgrounds. African
Americans often do not fit within the established diagnostic criteria, nor do they exhibit the same
biomarker profile as NHWs12. Lower tau levels, weaker correlation between cognition and the regions of
the brain most vulnerable to tau, and a higher prevalence of mixed pathology within African Americans
point to a unique race-specific mechanism and disease trajectory yet to be defined by the scientific and
medical community. Functional connectivity provides a method of examining neuronal alterations across
the disease spectrum that can model the dynamic interactions between regions that may more accurately
reflect cognitive changes, and respond to ischemic damage prevalent in the AA population.
Chapter 2 includes the analysis for Aim 1a, an analysis of default mode network connectivity and
an analysis of the role race in connectivity to biomarker relationships in the context of dementia. Chapter
3 includes analyses for Aim 1b, which includes analysis of functional connectivity of the DMN and its
subnetworks, and how these measures relate to regional hyperintensities, and the role of race. Chapter 4
includes both Aims 2 a & b; an analysis of putamen network connectivity, the role of hyperintensities,
and how race modifies some of these relationships.
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1.9
1.9.1

Specific Aims
Aim 1a: Determine the extent to which race modifies the relationship between connectivity of
the DMN subnetworks and AD biomarkers.

1.9.2

Aim 1b: Determine the extent to which regional WMH account for racial differences we
observe in DMN connectivity to biomarker relationships.

1.9.3

Aim 2a. Determine whether cortico-putamen connectivity correlates with AD biomarkers, and
whether race modifies these relationships.

1.9.4

Aim 2b. Determine whether regional WMH relates to connectivity and accounts for any
observed differences in connectivity to biomarker relationships.
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The following manuscript originally appeared in Translational neurodegeneration as:
Misiura, M.B., Howell, J.C., Wu, J. et al. Race modifies default mode connectivity in Alzheimer’s
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AIM 1A: RACE MODIFIES DEFAULT MODE CONNECTIVITY IN ALZHEIMER’S
DISEASE

Maria B Misiura, M.A. 1,2, J. Christina Howell, B.A.2, Junjie Wu PhD3, Deqiang Qiu, PhD,3, Monica W.
Parker, M.D.2, Jessica A.Turner, PhD1, William T Hu, M.D., PhD.2
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Departments of 2Neurology and 3Radiology, Emory University. Atlanta, GA

Abstract
Background: Older African Americans are more likely to develop Alzheimer’s disease (AD) than older
Caucasians, and this difference cannot be readily explained by cerebrovascular and socioeconomic factors
alone. We previously showed that mild cognitive impairment and AD dementia were associated with
attenuated increases in the cerebrospinal fluid (CSF) levels of total and phosphorylated t-Tau in African
Americans compared to Caucasians, even though there was no difference in beta-amyloid 1-42 level
between the two races.
Methods: We extend our work by analyzing early functional magnetic resonance imaging biomarkers of
the default mode network MRI between older African Americans and Caucasians. We calculated
connectivity between nodes of the regions belonging to the various default mode network subsystems and
correlated these imaging biomarkers with non-imaging biomarkers implicated in AD (CSF amyloid, total
tau, and cognitive performance).
Results: We found that race modifies the relationship between functional connectivity of default mode
network subsystems and cognitive performance, tau, and amyloid levels.
Conclusion: These findings provide further support that race modifies the AD phenotypes downstream
from cerebral amyloid deposition, and identifies key inter-subsystem connections for deep imaging and
neuropathologic characterization.
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2.1 Introduction
It is not well understood why older African Americans are twice as likely to develop Alzheimer’s
disease (AD) as older non-Hispanic Caucasian Americans (abbreviated as Caucasian hereafter).140,141
While vascular disease12,126,142 has been speculated to contribute to the disparities in AD risks, genomewide association and clinical studies suggest race/ethnicity (hereafter referred to as race), outside of these
factors, also modify the molecular pathways implicated in the development and manifestation of AD
pathology. For example, the APOE ε4 allele confers lower AD risks for African Americans than
Caucasians,135,143 the ABCA7 risk allele confers greater AD risks for African Americans than
Caucasians17, and AD is associated with less amnestic baseline and slower longitudinal decline in African
Americans than Caucasians on neuropsychological analysis.42 These cohort-level differences may reflect
intrinsic biological differences between race, lower correlation between clinically-suspected and
pathologically-confirmed AD (~75% accurate), recruitment bias in one or both races, or a combination of
these factors27,144. Data-driven strategies are therefore necessary to provide mechanistic correlates of
observed race-associated differences to more clearly understand AD disparity.
One such approach is to use etiologic biomarkers associated with hallmark AD pathology to
enhance the likelihood that those clinically suspected to have AD indeed have the pathology. We recently
showed that in a group of older adults with mild cognitive impairment (MCI) or AD dementia, African
Americans had lower cerebrospinal fluid (CSF) levels of t-Tau-related biomarkers than Caucasians15. This
is despite similar changes in CSF levels beta-amyloid 1-42 (Aβ42). We interpreted these findings as
preliminary evidence for divergent biomarker trajectories and these differences have now been validated
in one independent cohort in St. Louis and an independent younger cohort in Atlanta 145,146.
Because we have not identified a difference in atrophy patterns between African Americans and
Caucasians with AD, we hypothesized that rsfMRI would be a more sensitive approach to identify the
effect of race on AD-related neurological changes. We are particularly interested in resting state
functional connectivity, as alterations in connectivity can be detected well before disease onset147 and
track disease progression.148 To explore brain changes associated with AD which may differ between
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races, we analyzed functional connectivity (hereafter referred to as connectivity) in the default mode
network (DMN) using resting-state functional MRI (rsfMRI). The DMN is considered a potentially useful
imaging biomarker for AD that is more widely available than amyloid PET65,68,149–152.
In older adults, the DMN is broadly defined as correlated Blood Oxygen Level Dependent
(BOLD) signal among the precuneus, posterior cingulate cortex (PCC), the inferior parietal lobule (IPL),
the ventromedial prefrontal cortex (vmPFC). 68,153 The DMN overlaps with anatomical sites vulnerable to
amyloid deposition and atrophy in early AD, 154 and reduced connectivity between DMN nodes (intranetwork connectivity) mirrors the stage-wise t-Tau deposition on PET imaging45,155 even before there is
detectable atrophy.12 The trajectory of AD functional connectivity changes is complex. The
overwhelming majority of studies examining four DMN nodes reported reduced connectivity in AD
(dementia),61, 156, 67, 157, 158 with an exception reporting increased connectivity during early MCI.61
However, few studies used etiologic biomarkers to distinguish between cognitive impairment due to AD,
psychiatric illness, or cerebrovascular disease159. DMN hyperconnectivity has also been observed in
asymptomatic APOE ε4 carriers when compared to non-carriers,160, 161 sometimes decades before
symptom onset.162 DMN connectivity may therefore have different relationships with AD risks
(including risk genes), pathologic markers, clinical phenotypes, and disease stage, making inclusion of
etiologic and clinical biomarkers in AD-related DMN analysis critical to ensure the consistency of
findings.
As research on the DMN progresses, further fractionation of this complex network has revealed
synchronous bold activity in regions outside traditional definitions of the DMN. Core subsystems64
(dorsomedial, medial temporal lobe, and midline core) have been proposed to each contain key regions
which work in tandem to support cognitive processes in learning and memory, retrieval of
autobiographical information, self-referential processes,163, and social processing164. Dividing the DMN
into its subcomponents has thus far provided more sensitive timelines for disease progression in AD and
other neurological disorders156. Studies have shown that connectivity within the medial temporal lobe,
rather than average DMN connectivity between the four core nodes, more consistently relates to cognitive
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impairment in AD30,148; increases in connectivity within the anterior subsystems during early AD is more
consistently identified in studies analyzing DMN subsystems34,157; and memory impairment can be
associated with decreased intra-subsystem connectivity within the medial temporal lobe165 but increased
connectivity between dorsomedial and midline core subsystems166, 167.
The vast majority of studies analyze connectivity changes within diagnostic categories of normal
cognition (NC), MCI, and AD dementia. Given that differences in cognitive impairment between NC and
MCI and between MCI and AD dementia can sometimes be small, a continuous measure of cognition is
preferred168,169 especially when it remains controversial whether current diagnostic algorithms are valid in
African Americans (even with race-adjusted norms)12,49. Thus, we also use a composite measure of
cognitive performance derived from neuropsychological tests15 to serve as a continuous, rather than
categorical, measure of disease burden. We hypothesized that race modifies the relationship between
connectivity and AD-related cognitive impairment, and between connectivity and two CSF AD
biomarkers (Aβ42170 and t-Tau171). Furthermore, we specifically tested the generalizability of ADassociated connectivity changes between DMN nodes and between DMN subsystems to extend the AD
biomarker phenotype in African Americans.
2.2 Methods
Participants
This study analyzed previously collected data from a study that recruited self-reported
Non-Hispanic Whites and African Americans over the age of 65 across the diagnostic spectrum of
Alzheimer’s disease dementia including individuals with normal cognition (NC), individuals with mild
cognitive impairment (MCI), and individuals with Alzheimer’s Disease (AD)15. The study was approved
by the Emory University Institutional Review Board. Each participant underwent a detailed interview for
demographic information, self-reported race (Caucasians of Hispanic or Latino ethnicity were not
included in this study), vascular risk factors (coronary artery disease, congestive heart failure, atrial
fibrillation, hypertension, hyperlipidemia, diabetes, suspected transient ischemic attack), other medical
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comorbidities (e.g., cancer), and medications (e.g., use of angiotensin-converting enzyme inhibitors or
angiotensin II receptor blockers). Each participant was then assigned a diagnosis according to consensus
criteria including those for normal cognition (NC), MCI, and AD dementia (global Clinical Dementia
Rating of 1 or 2.) Cognitively impaired subjects suspected of having a non-AD dementia (vascular, Lewy
body, and frontotemporal dementia) were excluded. While our cohort was not age and gender matched
specifically, we did not find significant differences in age between races or gender (Table 1). As
previously reported, diabetes and hypertension were more common in African Americans than
Caucasians, but had lower brain total white matter hyperintensity (WMH) volumes than Caucasians.
Demographic data in table 1 refer to individuals who passed MRI quality control standards (n=137) as
described below.
Cognitive, genetic, and CSF biomarkers
Neuropsychological analysis was performed as previously described15. Briefly, each subject
underwent. Each subject also underwent a detailed neurologic examination and neuropsychological
analysis for assessment of function in cognitive domains. These included(1) memory (Consortium to
Establish A Registry for Alzheimer’s Disease word list delayed recall, Brief Visual Memory Test–
Revised [BVMT-R] delayed recall), (2) executive func-tion (Trail Making Test B, reverse digit span
[RD], Symbol Digit Substitution Test, and letter-guided fluency), (3) language (Boston Naming Test [60
items], category fluency), and (4) visuospatial function (Judgment of Line Orientation[JOLO], ReyOsterrieth complex figure test). With the exception of BVMT-R, JOLO, and RD, subtest Z-scores were
calculated according to published normative data, adjusting for age, sex, education, and race. Z-scores for
these three subtests were calculated using the same norms were used in Caucasians, but calculated using
Atlanta-based, cognitively normal African Americans because published norms generated mean Z-scores
of >2. Domain-specific Z-scores were calculated by averaging subtest Z-scores, and Z-scores for the four
domains were averaged to generate composite cognitive Z-scores. Subjects with MCI and AD dementia
had lower MMSE and cognitive Z-scores than subjects with NC (p <.01 for all comparisons, Table 1). In
addition, each subject underwent standardized collection of blood (for APOE and ABCA7 genotyping) and
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CSF without overnight fasting according to a modified Alzheimer’s Disease Neuroimaging Initiative
(ADNI) protocol as previously described.34
MRI acquisition and preprocessing
Each subject underwent MRI scanning using a modified ADNI protocol on a 3T scanner
(Siemens AG) which included a T1-weighted 3D MPRAGE sequence (TR/TI/TE = 1620/950/3msec, flip
angle = 30o, matrix = 192×256×160, and voxel size = 0.98×0.98×1mm3) and a 6 minute eyes-open resting
state functional MRI scan (TR/TE = 3000ms/32ms flip angle = 90o, field of view
(FOV) = 200 × 200 mm2, acquisition matrix = 64 × 64, voxel size = 3.1 × 3.1 × 3.5 mm3, slice = 33, time
point = 124) at the Emory Center for Systems Imaging. For rsf-MRI, we used the DPABI v4.0.190305
toolbox to preprocess the image data172 after discarding the first 10 volumes to allow the magnetization to
approach a dynamic equilibrium, and to allow for more time for our participants to get comfortable inside
the scanner158,173. Individual echo-planar imaging (EPI) data were slice time corrected. Participants whose
head motion exceeded 3.0 mm in translation or 3° in rotation were excluded. We further reduced the
confound of head motion by higher-order regression based on Friston's 24-parameter model 174, and the
effect of physiological artifacts by covarying signals from CSF space and white matter.175 EPI data were
normalized to a study specific template generated using the DARTEL algorithm in DPABI that is better
suited for populations with larger amounts of atrophy than standard normalization to the MNI template.176
A spatial filter of 6 mm full width at half maximum Gaussian kernel was used. Subsequently, a band pass
temporal filter (0.01–0.08 Hz) was applied to reduce the low-frequency drifts and high-frequency noise.
MRI Quality Control
To be eligible for this analysis, participants must have had a T1 suitable for use in
segmentation, as well as a usable resting state scan. To further eliminate confounds from head motion, we
removed anyone whose mean framewise displacement (MWFD) was 3mm and higher177. Among 145
subjects, 8 (5%) had rsf-MRI that did not pass quality control and were excluded from DMN analysis.
Table 1 displays demographic data only for individuals included in the MRI analysis (n=137), and Table
2 shows demographic data for individuals not included in the analysis. Compared to those included the
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analysis, those excluded did not differ significantly in age, gender, diagnosis, or race. There was no
significant difference in motion according to race or diagnosis.
Rsf-MRI Independent Component Analysis
We used a data driven approach (Independent
Component Analysis; ICA) using the Group ICA of fMRI Toolbox
v4.0b (GIFT) to identify large-scale brain networks.178,179 We first
performed independent components analysis with model-order of 80
to empirically derive our regions of interest which enabled us to
break the DMN into its various subregions, while still maintaining
appropriate degrees of freedom. ICA is a data driven approach that
allows for more adaptation to individual subject variability, which is
essential in special populations, particularly those with atrophy as in
our sample. The Default Mode and its subnetworks are relatively
robust, and can easily be identified in a higher order ICA model148,180.
We chose an ICA approach as it can be more sensitive to sample
characteristics, such as brain atrophy in older populations, than
standard atlas based seed-regions while still accurately identifying
regions of interest181,182.
To identify our regions of interest, we correlated all nonartifactual components183 with templates of the default mode network
and chose components with the highest correlation values to the
templates (0.80 cutoff threshold). Using the default mode network
subdivisions and coordinates outlined by Andrews-Hanna,64 we
Figure 2 Empirically derived
component maps of nodes according to
each DMN subsystem. TP= temporal pole,
vlTC= ventro-lateral temporal cortex,
dmPFC= dorsomedial prefrontal cortex,
dlTC= dorso-lateral temporal cortex, TPJ=
temporal parietal junction,

identified 11 components that contained our regions of interest for
the DMN subsystems. Components were manually confirmed using
the xjview toolbox(http://www.alivelearn.net/xjview/) to ensure that
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they contained only our regions of interest. Regions included the temporal pole (TP), lateral temporal
cortex (2 regions; ventrolateral (vlTC) and dorsolateral (dlTC), dorsomedial prefrontal cortex(dmPFC),
and the temporal parietal junction(TPJ) which comprised the dorsomedial subsystem. The
parahippocampal gyrus (pHG), hippocampus, and posterior inferior parietal lobule (pIPL) comprised the
medial temporal lobe subsystem. Finally, the precuneus, posterior cingulate (PCC), and ventromedial
prefrontal cortex (vmPFC) comprised the midline core subsystem (Fig. 1). We then calculated functional
connectivity in GIFT by correlating the time courses of signal fluctuations between the chosen
components, and obtained a correlation value for each region pair for a total of 55 measures of pairwise
connectivity.

Statistical Analyses
Statistical analysis was performed in IBM SPSS 24.0 (Armonk, NY) and R version 3.3.3.184
MANCOVA was used to determine if race modifies DMN connectivity according to cognition. First, we
analyzed baseline connectivity differences (only within controls). Measures of intra-network connectivity
between the DMN nodes were the dependent variables; cognitive scores, race, sex, age, and mean
framewise displacement (MFWD) were independent variables. Next, we analyzed data from all
participants using the same model, but included a higher order interaction term (race X cognitive scores).
Separate models to additionally account for effects of APOE ε4, ABCA7 risk allele, hypertension, total
white matter hyperintensity (WMH) volume, cardiovascular risk score, and diabetes on DMN
connectivity were also analyzed. For race-dependent connectivity changes, we accounted for multiple
comparisons through the Benjamin-Hochberg method.185 False discovery rate was limited to 10% given
our sample size and the number of nominally significant interactions with race.
The same analysis was repeated according to Aβ42 levels in all subjects. Because there is
significant overlap in t-Tau levels between NC and AD, we performed a third analysis according to t-Tau
levels only in subjects with reduced Aβ42 levels (<192 pg/mL)186consistent with cerebral amyloid
deposition.187 Compared to using uncorrected nominal p<0.05 as a threshold, we reduced the number of
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race-dependent node pairs from 23 to ten (six to four for cognition, from ten to two for CSF Aβ42, and
from seven to four for CSF t-Tau). Because we observed an over-representation of race’s effect on intersubsystem connectivity between nodes belonging to the midline core and dorsomedial (midlinedorsomedial) subsystems regardless of the measure used for AD (cognition, Aβ42, t-Tau), we used
bootstrapping (see below) to test whether the midline-dorsomedial connectivity was preferentially
modified by race in AD compared to intra-subsystem and other inter-subsystem node pairs. Finally, as
confirmation, we used analysis of covariance (ANCOVA) to determine whether race influenced the mean
midline-dorsomedial connectivity, midline-temporal connectivity, and dorsomedial-temporal connectivity
adjusting for diagnosis, age, and gender. Mean subsystem connectivity156 was calculated by averaging,
for each individual, all pairwise inter-subsystem node pair connectivity between the two subsystems in
question (15 pairs in midline-dorsomedial, 9 pairs in midline-temporal, and 15 pairs in dorsomedialtemporal).
Bootstrapping
We developed a novel simulation-based approach to test whether there was empirical enrichment,
or over-representation, for race modifying connectivity between midline core and dorsomedial
subsystems. To determine the likelihood of a concentration of significant interaction terms occurring by
chance alone, we first obtained p-values for all Race x Cognitive Z-score interaction term for all potential
node pairings (n=55; all subjects), and repeated the process for Aβ42 (n=55; all subjects) and t-Tau
(n=55; only in subjects with Aβ42 < 192 pg/mL).
As these AD features are inter-related, we pooled all 165 (55 x 3) p-values together, and used
bootstrapping analysis (“boot” package in R,188 with replacement) to create 1,500 simulated 3x5 (size of
midline-dorsomedial matrix) matrices of p-values. The number of “chance-only” matrices (out of 1,500)
with three or more significant p-values is thus the probability of an observed concentration in any random
3x5 matrix of node pairs resulting from chance alone. At the same time, because this probability can be
artificially reduced by a more stringent threshold at the matrix level (e.g., four or more significant pvalues), we created a second set of 1,500 simulated p-value matrices through the same bootstrapping
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process to represent the range of possible midline-dorsomedial p-values. Instead of drawing from all
potential p-values, these 1,500 matrices were then only sampled from p-values pooled from the 45
interaction p-values between midline-dorsomedial node pairs (n=15 each for Race x Cognitive Z-score,
Race x Aβ42, and Race x t-Tau) (Figure 2). The probability of having three or more significant p-value
in each matrix in this second bootstrap is then compared with the first using Chi-squared test. We
compared the proportion of significant vs. non-significant p values across the two bootstrapped
distributions. The null hypothesis for this test was that the number of samples that contained more than
three significant p values would not differ between the midline-dorsomedial bootstrap and the chanceonly bootstrap. We elected to use 1,500 as the bootstrap size as it is well within the commonly
recommended threshold,189 but still a tiny fraction of all possible combinations.

Figure 3 Illustrated workflow of the p-value bootstrapping analysis to confirm concentration of
race’s effect on midline-dorsomedial connectivity. Filled boxes represent node-pair connectivity
modified by race, and empty boxes represent node-pair conne
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2.3 Results
Baseline connectivity differences
We first compared baseline connectivity profiles between
older African Americans and Caucasians with NC (n=58, Fig 3).
Compared to Caucasians, African Americans had lower connectivity
between the precuneus and the ventro-lateral temporal cortex (by
0.31, 95 %
and

CI -0.16, -0.46, p=0.01), the inferior parietal lobule

parrahippocampal gyrus (by -0.15, 95 % -0.28, -0.03, p=0.01), and the
temporal pole and hippocampus (by 0.19, 95 % CI -0.33, -0.04,
p=0.01; Table 3). There were otherwise no baseline connectivity
differences in the remaining 52 inter-nodal connectivity values
between the two racial groups.

Race-independent changes centered in the medial
temporal lobe subsystem of DMN
Because AD is characterized by reduced CSF Aβ42,
increased CSF t-Tau, and cognitive impairment, we first analyzed the
relationship between DMN connectivity, AD biomarkers (cognitive
Z-score, Aβ42, t-Tau), and race to determine when race did not modify
Figure 4 Baseline connectivity
differences between older African Americans
and Caucasians with NC (p<0.04). Among nodes
distributed along the three subsystems, three
node pairs’ connectivity differed between the
races. In all instances, African Americans
(green) with NC had lower connectivity between
these node pairs than Caucasians (blue; bars
represent mean values). TP= temporal pole,
vlTC= ventro-lateral temporal cortex, dmPFC=
dorsomedial prefrontal cortex, dlTC= dorsolateral temporal cortex, TPJ= temporal parietal
junction, pIPL= posterior inferior parietal lobule,
pHG=parrahippocampal gyrus, vmPFC= ventromedial prefrontal cortex, PCC= posterior
cingulate cortex.

the relationship between AD biomarker and connectivity. In both African
Americans and Caucasians, lower (more abnormal) Aβ42 levels
correlated with decreased connectivity between the inferior parietal lobule
and the parrahippocampal gyrus (B= -.01, t(167)=-2.14, p =0.02).
Because there is overlap in CSF t-Tau and p-Tau181 levels between
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controls and AD even though their levels are elevated at the group level, we restricted t-Tau-related
analysis to those with Aβ42 levels consistent with AD (< 192 pg/mL).
This also showed higher (more abnormal) t-Tau levels to correlate with decreased connectivity
between multiple region pairs within the DMN, including hippocampus-temporal pole (B= .04,
t(167)=1.58, p =.02) (Figure 4). Connectivity correlated with cognitive impairment regardless of race
appeared to occur between the medial temporal lobe and the midline core subsystems, and between the
medial temporal lobe and the dorsomedial subsystems (Table 4, Figure 4).

Figure 5 Race independent connectivity associations with biomarkers. Lines represent regions
pairs for which connectivity was significantly related to the particular AD biomarker regardless of race
(dashed line indicate CSF tau, solid line indicates cognition, and dotted line indicates CSF amyloid, red
for positive relationship, blue for negative relationship, and grey for a relationship that did not survive
correction for multiple comparisons). TP= temporal pole, vlTC= ventro-lateral temporal cortex, dmPFC=
dorsomedial prefrontal cortex, dlTC= dorso-lateral temporal cortex, TPJ= temporal parietal junction,
pIPL= posterior inferior parietal lobule, pHG=parahippocampal gyrus, vmPFC= ventro-medial prefrontal
cortex, PCC= posterior cingulate cortex.
Race selectively modified the relationship between AD biomarkers and connectivity only
between the MTL and Dorsomedial subsystem nodes
We next examined node pairs whose connectivity relationship with AD biomarkers was modified
by race (Table 5, Figure 5). In Caucasians, greater cognitive impairment was associated with decreased
DMN connectivity between the precuneus and lateral temporal cortex, and between the precuneus and the
temporal pole. However, the opposite is true in African Americans, with greater cognitive impairment
associated with increased connectivity between these same regions. Similarly, lower (more abnormal)
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Aβ42 levels correlated with greater connectivity between the precuneus and both lateral temporal cortex
and dorsomedial prefrontal cortex only in African Americans. Higher t-Tau levels (in those with Aβ42
levels < 192 pg/mL) also correlated with greater connectivity between the lateral temporal cortex and
precuneus, and between the temporal pole and both vmPFC and precuneus, and between the hippocampus
and PCC, again only in African Americans. Adjusting for risk genes (ABCA7, APOE) and other factors
(hypertension, cardiovascular risk score, white matter hyperintensities, and diabetes) did not significantly
influence connectivity values and race-associated differences persisted in connectivity relationship.

Figure 6 Connectivity and biomarker relationships in African Americans for which interaction
term regression coefficient (race X biomarker) is significantly greater than zero. Figure depicts regression
relationship between connectivity and biomarkers in African Americans. Red line indicates connectivity
increases as disease burden for that biomarker increases (see indication for each biomarker). Blue line
indicates connectivity significantly decreases as disease burden for that biomarker increases (see
indication for each biomarker). Gray outline indicates no significant relationship for African Americans
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between connectivity and biomarker. Dashed line indicate CSF tau, solid line indicates cognitive
performance, and dotted line indicates CSF amyloid. *=NHWs had significantly stronger (more negative)
relationship than AAs. TP= temporal pole, vlTC= ventro-lateral temporal cortex, dmPFC= dorsomedial
prefrontal cortex, dlTC= dorso-lateral temporal cortex, TPJ= temporal parietal junction, pIPL= posterior
inferior parietal lobule, pHG=parahippocampal gyrus, vmPFC= ventro-medial prefrontal cortex, PCC=
posterior cingulate cortex.
Visualizing race-independent (Fig 4) and race-dependent (Fig 5) DMN changes in AD, we
observed a pattern of race-specific changes involving connectivity between two subsystems. Whereas
race-independent connectivity occurred between each pair of subsystems, nine out of ten race-dependent
connectivity changes were between the midline core and dorsomedial subsystems. For each subject, we
calculated a mean connectivity value by averaging the all node-pair connectivity values between two
subsystems.
We further tested whether the midline-dorsomedial connectivity had an over-representation of
node pairs whose connectivity was modified by race compared to the rest of DMN, we used bootstrapping
(with replacement) to create 1,500 simulated 3x5 matrices drawn from midline-dorsomedial node pairs
and 1,500 simulated matrices drawn from all node pairs. We found that drawing from the midlinedorsomedial matrices was more likely to result in identifying at least three significant race X AD
biomarker effect than drawing from all node pairs: 791/1500 in the midline-dorsomedial sample vs.
192/1500 in the chance-only sample, X2 (2, N=3000)=487.53, p= 0.00001. ANCOVA adjusting for
diagnosis, age, and gender confirms a main effect for race (F(2, 119)=3.255, p=0.074) for mean midlinedorsomedial connectivity, but not for mean midline-temporal connectivity (F(2,119)=0.061, p=0.8060) or
mean dorsomedial-temporal connectivity (F(2,119)=1.418, p=0.236).
2.4 Discussion
Consistent with previous work, we found AD to alter connectivity between the medial temporal
lobe and dorsomedial subsystems, but we identify race-specific changes associated with these alterations
190,191

. Importantly, we extend the effect of race on AD-related connectivity from the inter-nodal level to

the inter-subsystem level through a novel analytical strategy. To the best of our knowledge, this is the
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first attempt to statistically identify enrichment of a factor’s effect on connectivity between two
subsystems across multiple related measures (cognition, Aβ42, t-Tau). The implication of this intersubsystem effect is not well understood. Other conditions previously observed to confer similar
specificity on inter-subsystem connectivity include PTSD,192 depression,193 and schizophrenia.194
Interestingly, some of these conditions show racial disparities (schizophrenia195 and PTSD196 are more
common in African Americans than Caucasians). The inter-subsystem specificity may reflect shared
vulnerability to neuropsychiatric disorders in African Americans, existence of disease subtypes, or
divergent disease-associated pathways. We discuss these possibilities in the context of AD in African
Americans below.
In contrast to a uniformly slow disease process in African Americans, it is also possible that the
multiple pathologic processes in AD may not proceed at the same pace in African Americans. In postmortem studies of AD (involving primarily Caucasians), Aβ42-rich neuritic plaques are found early in the
medial temporal as well as neocortical regions154. In contrast, tau-related changes appear in the medial
temporal lobe before a stage-wise involvement of the frontal and then parietal cortical regions154. If we
can interpret these observations as early co-localization of neuritic plaques and neurofibrillary tangles in
the medial temporal lobe, the race-independent effect on inter-subsystem connectivity involving this
region is in keeping with shared early AD changes by older African Americans and Caucasians when CSF
Aβ42 alterations are detectable. The attenuation of midline-dorsomedial connectivity in African
Americans could then be interpreted as early compensation when AD is mild, or as pathological hyperconnectivity 197,198. This would support the diminished cognitive reserve hypothesis in African Americans
(potentially due to vascular disease199), and the prevailing longitudinal models that African Americans
have slower decline in the presence of AD pathology.12,200 At the same time, the correspondence between
ante-mortem DMN connectivity changes and post-mortem lesional mapping is known to be imperfect.
For example, we found connectivity involving the posterior inferior parietal lobule (pIPL, a node in the
medial temporal lobe subsystem) to be affected by AD independent of race. This may suggest pIPL to be
a locus of early AD pathology, but neurofibrillary tangles do not appear in this region until later in AD.201
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The identified disparities in cognition and its relationship to functional connectivity are in
keeping with current understanding of the African American cognitive profile in AD. African Americans
exhibited an inverse relationship between cognition and FC compared to Caucasians such that as
cognitive impairment increased, connectivity also increased. Typically, in AD, connectivity decreases as
cognitive impairment increases. However, an increase in connectivity can be a result of disease
processes198. An increase in connectivity in the mild cognitive impairment stage of AD, and in the
presence of vascular disease is a fairly common finding199. Africans Americans generally exhibit slower
cognitive decline in AD, and this increased connectivity could reflect an extension of early disease
processes that generate the increased connectivity seen in many MCI studies.
Other than milder AD-related tau pathology, the selectivity of race for midline-dorsomedial
connectivity could result from non-AD pathologies outside these two subsystems or neuro-protective
changes along the tracts connecting two subsystems. Limited autopsy studies have shown African
Americans more likely than Caucasians to have mixed AD and vascular lesions,114 and we previously
showed in this cohort that African Americans experienced greater cognitive impact than Caucasians from
the same degree of WMH.15 In the current study, we did not find total WMH volume to be related to race
and connectivity. However, the impact of regionally specific WMH has yet to be examined. The baseline
differences in connectivity suggest existing differences in brain function separate from disease
mechanisms that could be related to vascular disease, but the nature of these differences is not well
understood, and the inclusion of vascular disease in our regression models did not alter our results.
Although hypertension was more prevalent in our African American cohort, and African Americans had
elevated cardiovascular risk scores, when we included this variable in our analyses, it did not explain the
variability associated with race. Our identification of race-associated changes in midline-dorsomedial
connectivity would support a search for WMH changes outside of these two subsystems. Alternatively,
Caucasians may be more likely to have WMH between these two subsystems.202 The vascular load in
our cohort was mild to moderate, as it is not feasible, or ecologically valid to recruit older patients with
minimal vascular disease. There are a variety of risk factors and contributing comorbidities for
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Alzheimer’s Disease. It is possible that the various risk factors associated with AD may be different
across different ethnic groups, such that AAs may have an increased vascular component of AD, while
exhibiting AD pathology sufficient to meet diagnostic thresholds. WMH and AD are not mutually
exclusive, and many have stated that WMH are a core feature of AD203,116, and a better predictor of
disease burden in African Americans204. Future research will explore region-specific WMH between races
and whether these differences relate to observed connectivity biomarker relationships.
It would be remissive to not explore social factors which may contribute to these biological
disparities. The current work is the first to establish AD-related connectivity difference between races,
and extends the neurobiological phenotype of AD in African Americans beyond a higher prevalence.
How historical and current social inequalities may interact with genetic and environmental risks to give
rise to these biological endpoints remains unknown. A variety of social disparities including income
(amount vs. purchasing power), education (length vs. quality), and discrimination may additively or
synergistically converge on the same biological endpoints. When analyzed separately, these factors may
individually correlate with racial disparity but fail to capture the entire range of exposures facing different
groups. For example, individuals who experience racial discrimination and perceive it as such are more
likely to have higher blood pressure and increased psychological distress,205,206,207 which in turn are risk
factors for AD.208 Chronic stress also increases connectivity between the DMN and other networks at
least in young adults,209 and may in part account for baseline and AD-related connectivity differences
between the two racial groups. We did not include household income as a surrogate measure of lifelong
socioeconomic status because the two measures poorly correlate in retired people, and the sample size
limited our ability to interpret results when we introduced a measure such as the Area Deprivation
Index210. A larger sample size will be necessary to test mediation effects between discrimination, stress,
cardiovascular disease, and negative health outcomes, and cohort studies need to explore biologically
meaningful methods to characterize individual and group-based experiences of injustice.
While we present the first biomarker-informed analysis of DMN inter-subsystem connectivity in
African Americans, there are a number of limitations to our study. We tested two common AD risk
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genotypes as mediators for race-associated differences, but we did not perform extensive genomic
association analysis because of sample size. While we observed multiple race-associated differences in
DMN connectivity using ICA, we did not perform seed-based analysis of other large-scale brain networks
(e.g., salience network). This cohort’s African American participants had similar years of education and
socioeconomic status as their Caucasian counterparts, but other medical, psychiatric, or psychosocial
differences could contribute to inter-subsystem connectivity differences. We did not identify a modifying
effect of race on mean connectivity strength between the MTL and dorsomedial subsystem. Lastly, both
racial groups include heterogeneous genetic backgrounds and in some cases mixed genetic heritage, so
our results should be interpreted at the cohort level rather than the individual level. Nevertheless, we
present additional evidence that AD is associated with systematic biomarker differences between older
African Americans and Caucasians. Because CSF t-Tau-related findings similar to ours were replicated
in a separate US cohort,2 independent replication of these DMN findings will further highlight the
importance of diversity, inclusion, and disparities in on-going effort to elucidate mechanism-related
biomarkers in AD.
2.5 Conclusions
We previously identified that African Americans and Caucasians share the same AD-associated
CSF alterations related to amyloid deposition, but different CSF t-Tau biomarker levels regardless of AD
status.15 Here we extend our findings to show older African Americans and Caucasians have similar ADassociated subsystem connectivity changes involving the medial temporal subsystems. However, we also
demonstrate race-specific patterns of connectivity between the midline core and dorsomedial subsystems,
that are in-line with current studies that suggest divergent tau relationships between races. Race modified
the relationships between AD biomarkers and connectivity between the medial temporal lobe and
dorsomedial subsystems. We thus propose adding DMN connectivity to the list of biomarkers with racedependent alterations in AD. Similar to CSF, rsfMRI profiles for AD established in pre-dominantly
Caucasian cohorts may under-diagnose the disease when applied directly to African Americans, and
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negatively impact the interpretation of clinical trial outcomes when rsfMRI is used as surrogate marker of
AD. The current work further provides specific regions of interest for imaging-based and molecular
investigation of disease mechanisms.
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2.6 Chapter 2 Tables

Table 1 Demographic information. Sample reported here is the final imaging cohort of all individuals who
passed imaging quality control. Note: T-tests were performed to compare races in the whole cohort and
within each diagnostic category. *p<.05, **p<.001. MMSE and CogZ scores were significantly different
between diagnostic categories such, NC having highest MMSE scores and AD having lowest(MMSE: NC
vs MCI, p= .007, MCI vs AD, p<.0001, CogZ: NC vs MCI, p<.0001, MCI vs AD, p<.0001).
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Age,
years
(SD)
Gender
Years of
Education
(SD)
MMSE
(SD)
Cognitive
Z Scores
(SD)
White
Matter
Hyperinte
nsity
volume
(mm3)
Having A
BCA7 risk
allele, (
%)
Have
Diabetes,
(%)
Have
Hypertens
ion(%)
CSF
Aβ42,
pg/ml
(SD)
CSF tTau,
pg/ml
(SD)
CSF pTau,
pg/ml
(SD)
CSF tTau/Aβ42

Overall
(N=137)
African
Caucasi Americ
an
an
(n=72)
(n=65)
70.90(7 69.20(7
.84)
.49)

Normal
cognition
African
Caucasi Americ
an
an
(n=31)
(n=27)

MCI
African
Caucasi America
an
n
(n=25)
(n=28)

AD
African
Caucasi America
an
n
(n=16)
(n=10)

71.65(8.
39)*
19(12)

67.48(6.
17)*
17(10)

71.52(5.
82)
15(10)

70.07(7.7
4)
12(16)

68.50(9.
41)
9(7)

71.4(9.6
5)
6(4)

16.81(2.
69)
28.84(0.
86)
0.07(0.5
1)

15.78(2.
66)
28.00(1.
86)
0.11(0.5
1)

17.08(2.
58)
27.64(1.
68)
0.88(0.8
6)

16.29(2.8
1)
26.67(2.3
4)
0.67(0.59
)

14.19(1.
94)
21.37(3.
38)
2.24(0.6
6)

16.80(3.
55)
20.22(6.
18)
2.36(1.0
2)

3984.40 3886.03 3306.81
(4110.1 (4964.9 (3337.3
0)
3)
2)

2440.93
(2576.1
5)

4018.66( 4313.70(
4080.03) 5330.60)

5243.68( 6730.21(
5333.14) 7607.48)

29.00

44.40

24.00

50.00

12.50

30.00

6.50**

33.33**

0*

28.60*

12.50*

50.00*

45.83** 72.31** 45.16

62.96

56.00

78.57

31.25*

80.00*

148.35(
95.02)

168.48(
128.86)

199.93
(132.30)

165.27
(89.8)

199.11
(141.02)

134.69
(90.99)

77.65(47 133.55
.39)
(140.71)

72.84(4
9.63)**

40.92(2
0.79)**

51.68
(30.96)*
*

36.04
(11.63)
**

63.99
(33.71)*

35.44
(13.67)*

108.48
(77.43)

75.8
(33.52)

17.58
(8.97)*
*
0.73
(0.91)*

25.81
(12.47)
**
0.24
(0.22)*

23.47(9.
71)**
0.46(0.7
4)*

14.05
(5.07)*
*
0.15
(0.12)*

25.01
(13.42)*
0.44(0.4
2)*

17.74(7.2
1)*
0.22(0.14
)*

33.53(14
.64)
1.36(1.1
6)

24.54(10
.27)
0.55(0.4
1)

35(37)
16.32(2
.85)

43(29)
16.15(2
.85)

26.32(4
.90)
0.78(1.
12)

26.91(3
.57)
0.72(0.
99)

23.67*

5.67**

43.10*

33.80**
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Table 3

0.89(2.
62)

0.82(1.89)

Normal
cognition
African
Caucasi Americ
an
an
(n=4)
(n=2)
71.65(8. 67.48(
39)
6.17)
16.8(2.6 16.78(
9)
2.66)
28.9(0.8 27.75(
6)
1.86)
0.02(0.6 0.01(0.
2)
71)

1

2

0

1

1

1

0

1

0

1

0.0

0

2

2

1

1

1

1

Overall (N=8)

Age, years
(SD)
Years of Education
(SD)
MMSE (SD)

Cognitive Z Scores
Having ABCA7 risk
allele,
(number)
Have Diabetes,
(number)
Have Hypertension
(number)
CSF Aβ42, pg/ml
(SD)
CSF t-Tau, pg/ml
(SD)
CSF p-Tau, pg/ml
(SD)

Caucas
ian
(n=5)
69.78(
5.83)
16.82(
2.85)
27.82(
4.90)

African
American (n=3)
65.20(10.25)
16.25 (2.63)
28.91(3.57)

MCI
African
Caucasi Americ
an
an
(n=1)
(n=1)
71.52

70.07

17.08

16.29

27.64

26.67

0.84

0.75

133.34
200.93( 164.27
(95.02) 139.81(140.36)
132.40) (98.6)
201.11
134.69
72.84(
51.68(3 36.04(
49.63) 40.92(20.79)
0.96)
11.63) 63.99
35.438
42.71
37.44
22.95
(20.98) 29.90 (15.60)
(16.29) (8.46)
29.65
17.25
0.79(0.
0.85(0.8 0.15
CSF t-Tau/Aβ42
81)
0.26(0.21)
7)
(0.16)
0.46
0.22
Table 2 Demographic information for individuals excluded from analysis who did not pass QC
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Unadjusted Storey’s
Connectivity
B (95% Confidence interval)
p
q
0.137
-0.19(-0.33, -0.04)
0.01
Temporal Pole to Hippocampus
Ventro-Lateral Temporal Cortex
<0.001
-0.31(-0.46, -0.16)
0.01
to Precuneus
0.495
Inferior Parietal Lobule to
-0.15(-0.28, -0.03)
0.01
Parrahippocampal gyrus
Table 3 Baseline differences in functional connectivity between African Americans with NC and
Caucasians with NC, adjusting for age, gender, and APOE ε4 allele.
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Subsystems

MTL to
MTL

MTL to
midline core

MTL to
dorsomedial

Connectivity

Factor

Posterior IPL
to
Hippocampus
Posterior IPL
to ParraHippocampal
gyrus
Posterior IPL
to Ventromedial
prefrontal
cortex
ParraHippocampal
gyrus to
Precuneus
Temporal
Pole to
Hippocampus

Race
t-Tau

B (95% Confidence
Interval)
0.019(-0.29, -0.05)
0.002( 0.00, 0.003)

Unadjusted p

Storey’s
q

0.387
<0.001
<0.001

Race

0.32(-0.14, .25)

0.710

Aβ42

0.02(0.008, 0.40)

0.010

Race

-0.05(-0.30, 0.20)

0.675

t-Tau
Race

0.002( 0.00, 0.003)
-0.10( -0.30, 0.23)

0.001
0.358

0.004

t-Tau
Race

0.002(0.00, 0.002)
-0.10(-0.30, 0.10)

0.008
0.337

0.147

t-Tau

0.002( 0.00, 0.003)

0.009

0.247

1.000

Table 4 Factors associated with AD biomarkers (unadjusted p ≤ 0.01) independent of race,
adjusting for age, gender, mean framewise displacement, and APOE ε4 allele. Unadjusted p-values which
remain significant after Benjamini-Hochberg step-up correction for multiple comparisons are bolded.
Storey’s q-values are also shown with FDR < 10%. MTL= Medial Temporal Lobe. IPL= inferior parietal
lobule.
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Subsystem

Connectivity
Pair
Dorsomedial
prefrontal
cortex to
precuneus

Ventrolateral
temporal
cortex to
precuneus

Dorsomedial
to midline
core

Dorsomedial
prefrontal to
posterior
cingulate
cortex

Temporal
Pole
to precuneus

Dorso-lateral
temporal
cortex
to precuneus

MTL to
midline core

Storey’s
q

Variable
Name
Race
Cognitive
impairment
Race *
Cognitive
impairment

B(95 %
Confidence Interval)
-0.02( -0.30, 0.25)

Unadjusted p

0.04( -0.13, 0.04)

0.292

-0.14( 0.07, 0.25)

0.005

Race

-0.24( -0.59, 0.11)

0.170

-0.08( -0.02, 0.19)

0.103

0.18( 0.02, 0.17)
-0.05(-0.32, 0.21)
-0.003( -0.02, -0.002)
0.02( -0.03, -0.0002)

0.001
0.695
0.712
0.001

0.29( 0.08, 0.50)

0.007

0.05( -0.15, 0.03)

0.407

0.007
0.667
0.345

Race * Aβ42
Race
t-Tau

0.18( 0.02, 0.17)
0.05( -0.18, -0.29)
0.0003( 0.00, 0.01)
-0.001( -0.002, 0.00001)
-0.80(-0.29, 0.13)
-0.002( -0.01, -0.001)

Race *t-Tau

0.003( 0.001, 0.006)

0.005 0.069

Race

-0.21(-0.12, 0.36)

0.112

Aβ42

0.345

Race * Aβ42

0.0002( -0.0001, 0.01)
-0.002( -0.003, 0.00001)

Race

-0.21(-0.43, 0.02)

0.070

t-Tau

-0.001( -0.002, -0.02)

0.066

Race * t-Tau

0.004( 0.001, 0.006)

0.003 0.083

Race
Cognitive
impairment
Race *
Cognitive
impairment
Race
t-Tau

-0.074(-0.20,0.54)

0.004

0.27(-0.04,0.09)

0.001

Cognitive
impairment
Race *
Cognitive
impairment
Race
t-Tau
Race * t-Tau
Race
Cognitive
Impairment
Race *
Cognitive
impairment
Race
Aβ42

0.20( 0.05, 0.25)
-0.001( -0.22, 0.22)
-0.001( -0.03, 0.002)

0.861

0.092

0.055

0.055

0.096

0.004

0.073
0.442
0.736

0.002 0.055

0.002 0.055
0.900
0.199
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Posterior
cingulate to
hippocampus Race * t-Tau
0.003( 0.001, 0.052)
0.004
0.073
Table 5. Factors differentially associated with AD biomarkers according to race (unadjusted
p≤0.01), adjusting for adjusting for age, gender, mean framewise displacement, and APOE ε4 allele.
Unadjusted p-values which remain significant after Benjamini-Hochberg step-up correction for multiple
comparisons are bolded. Storey’s q-values are also shown with FDR < 10%. MTL= Medial Temporal
Lobe. IPL= inferior parietal lobule.
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3

Aim 1B: WHITE MATTER HYPERINTESITIES DO NOT ACCOUNT FOR
CONNECTIVITY DIFFRENCES ACCORDING TO RACE.

3.1 Introduction
Previous research has identified race associated differences between brain connectivity and
Alzheimer’s disease burden209. As defined by Andrews-Hanna, the default mode network is composed of
3 functionally distinct subsystems (dorsomedial, midline core, and medial temporal subsystem) 190.
Connectivity between the default mode network typically declines as Alzheimer’s disease progresses 59.
However, this finding has primarily been replicated in Non-Hispanic Whites (NHWs) with middle to high
socio-economic status20. In a previous study, we investigated Alzheimer’s disease biomarkers in the form
of CSF tau, Aβ42, and cognitive performance and their relationship to default mode subsystem
connectivity in a sample including both African Americans and NHWs. Within NHWs, as AD disease
burden increased, connectivity between the dorsomedial and midline core subsystems typically decreased.
However, within African Americans, as disease burden increased, connectivity between these same
subsystems increased, even after for controlling for APOE e4 phenotype, and total WMH volume. A
potential explanation for this discrepancy was that African Americans had differences in the regional
distribution of white matter hyperintensities, as AAs had higher percentages of vascular disease and type
2 diabetes210. As the regional white matter hyperintensity volumes became available, we analyzed the
plausibility of this explanation. In this study, we examined regional white matter hyperintensities in DMN
subsystems, as well as other subcortical structures to determine whether WMH explained the increase in
connectivity relate to AD observed in African Americans.
3.2 Methods
Participants
We used previously calculated functional connectivity values of a cohort that was ethnically
similar to our previously studied cohort, with the exception that this cohort did not contain any AAs with
Alzheimer’s disease (only NC and MCI). Briefly, each participant underwent a detailed interview for
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demographic information, self-reported race (Caucasians of Hispanic or Latino ethnicity were not
included in this study), vascular risk factors (coronary artery disease, congestive heart failure, atrial
fibrillation, hypertension, hyperlipidemia, diabetes, suspected transient ischemic attack), other medical
comorbidities (e.g., cancer), and medications (e.g., use of angiotensin-converting enzyme inhibitors or
angiotensin II receptor blockers). Each participant was then assigned a diagnosis according to consensus
criteria including those for NC, MCI, and AD dementia (global Clinical Dementia Rating of 1 or 2.)
Cognitively impaired subjects suspected of having a non-AD dementia (vascular, Lewy body, and
frontotemporal dementia) were excluded. Information for this cohort is available in the “cohort 1”
information in chapter 4, table 1.
MRI data collection & Analysis
Scanning protocol included a T1-weighted 3D MPRAGE sequence (TR/TI/TE =
2400/1060/2.31msec, flip angle = 8o, matrix =320x300, and voxel size = 0.8×0.8×0.8mm3) and a 6 minute
eyes-open resting state functional MRI scan (TR/TE = 724ms/32ms flip angle = 52o, field of view
(FOV) = 220 × 220 mm2, acquisition matrix = 104 × 104, voxel size = 2 × 2 × 2 mm3, slice = 91, time
point = 550), and a T2-weighted Fluid attenuated inversion recovery (FLAIR) scan (TR/TI/TE =
9000/2500/91 msec, flip angle = 150o, matrix =256x256, and voxel size = 0.8×0.8x5mm3).
We conducted preprocessing pipelines with identical procedures for each cohort. To control for
the difference in scanning parameters, we included cohort as a fixed effect in our statistical models. We
utilized a standard preprocessing pipeline utilizing the DPARSFA toolbox 170. The first 10 timepoints
were removed, scans were slice time corrected, manually re-oriented, realigned, normalized and smoothed
using the DARTEL & algorithm211. This algorithm is more appropriate than standard normalization to the
MNI template for special populations, such as those with atrophy. We then performed nuisance covariate
regression (Friston’s 24 parameter head motion regressors, CSF, WM). We further removed motionconfounds using ICA-AROMA and applied a high pass filter.
Regional WMH analysis
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Regional WMH volumes were derived from T2-weighted fluid-attenuated inversion recovery
images software developed by researchers in the Brickman Lab at Columbia University 212. Briefly, each
participant's fluid-attenuated inversion recovery image was corrected for intensity normalization, then
skull-stripped and intensity normalized again. The skull-stripped images were sent through a high pass
filter at the mode of the distribution of the image voxel intensity values. A half Gaussian mixture model
was fit to the log-transformed histogram of the intensity values of each image. The Gaussian distribution
that encapsulated the highest intensity values defined the hyperintense voxels and was labeled. Any
cluster of labeled voxels that comprised fewer than five voxels was removed from the mask. The labeled
images were visually inspected and false positives removed. The number of labeled voxels was summed
and multiplied by voxel dimensions to yield a total volume in cm3. We obtained FLAIR data from
individuals in Cohort 1 (Table 7) and performed this analysis on these 66 individuals.
Seed based analysis
We performed a seed based analysis using the regions described by Andrews hanna, et al.62 in the
3 DMN subnetworks, namely: the Dorsomedial subsystem (DM): temporal pole, temporal parietal
junction, lateral temporal cortex, dorsomedial prefrontal cortex; Medial temporal lobe subsystem (MTL):
Hippocampal formation, parahippocampal cortex, retrosplenial cortex, posterior inferior parietal lobule,
ventromedial prefrontal cortex; Midline core (MC): anterior medial prefrontal cortex, posterior cingulate
and precuneus. We calculated measures of pairwise connectivity between each pair of regions, for a total
of 56 measures of pairwise connectivity.
DMN WMH value
To obtain measures of DMN WMH across the subnetworks, we added together volumes across
the subnetworks to obtain a volume of WMH for each subnetwork. For the MTL we included bilateral
Hippocampal formation, parrahippocampal cortex, retrosplenial cortex, posterior inferior parietal lobule.
For the MC we included the anterior medial prefrontal cortex and posterior cingulate and precuneus. For
the DM subsystem we included temporal pole, temporal parietal junction, lateral temporal cortex,
dorsomedial prefrontal cortex.
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Statistical analysis
DMN WMH across races
To determine whether there was a difference between racial groups in DMN WMH volume, we
constructed one multivariate linear model with the DMN WMH volumes as the outcome variable. Racial
group was modeled as a fixed factor, and our covariates were age, gender, and APOE e4 status.
DMN WMH and connectivity
Because we previously identified racial differences in the relationships between connectivity and
AD biomarkers for connectivity between the midline core and dorsomedial subsystems, we focused on
these connectivity measures for the WMH analysis. We constructed linear regression models with our
connectivity measures between the nodes of the midline core and dorsomedial subsystems as our outcome
variables, and race and WMH volume as our independent variables of interest, while controlling for age,
gender, and APOE status. Additionally, we constructed a race by diagnosis interaction term to determine
whether the relationship between WMH and connectivity differed according to racial group.
To determine whether WMH within DMN nodes accounted for the racial differences that we
identified in our previous work, we constructed Race X AD biomarker interaction terms (CSF Aβ42, CSF
tau, and MoCA scores). We used these biomarker interaction as dependent variables, with the
aforementioned covariates. We then included the three default mode WMH scores as independent
variables to determine whether WMH accounted for racial differences we observed.
3.3 Results
DMN WMH across races
There was no significant difference between racial groups in WMH volume of the DMN
subnetworks: DM(B=0.02, t(3,72)=1.24, p=0.22), MTL(B=0.004, t(3,72)=0.16, p=0.88), MC(b=0.02,
t(3,73)=0.42, p=0.68). The only subnetwork that had a large proportion of individuals that did not have
any WMH was the DM subnetwork. Chi-squared tests for distribution of WMH across races for this
subnetwork were not significant.
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DMN WMH and connectivity
In this re-analysis of the data, we were able to replicate one of our previous findings. There was a
significant race x CSF Aβ42 interaction term for connectivity between the dorsomedial prefrontal cortex
and the precuneus/posterior cingulate such that as CSF Aβ42 decreased, connectivity increased between
these regions within AAs(B=-0.002, t(5,26)=-2.02, p=0.05). We were not able to replicate our previous
findings according to CSF t-Tau and cognition (Table 6).
WMH volume within the specific regions of interest as well as within the midline core and
dorsomedial subsystems was not related to our interaction terms. Because we had such a small number of
regions for which the race X biomarker term was significantly relate to connectivity, we also included the
dorsomedial prefrontal cortex and precuneus WMH volumes in our analysis. The inclusion of subsystem
total WMH volumes within the MC, DM, and regional dorsomedial prefrontal cortex and precuneus
WMH volumes into our model did not reduce the significance of the interaction term for the Aβ42 X
Race interaction term.
3.4 Discussion
DMN white matter hyperintensity volumes were not significantly different between races, nor
were there distributional differences between races. This indicates that the underlying cause of the
disparate connectivity to biomarker relationships that we previously observed may not be the presence of
WMH within these nodes. These findings lend credence to the hypothesis that WMH and Abeta have
separate etiologies, but these findings should be considered with caution for the reason mentioned below.
While we cannot say definitively that DMN WMH do not account for the observed differences in race to
biomarker relationships, this preliminary data does suggest that the WMH in the DMN do not have a
robust effect on connectivity. Other hypotheses about the nature of the disparities are that African
American connectivity profiles may be different as a result of tau distribution, as African Americans have
lower tau.
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While understanding the mechanism behind functional connectivity disparities has significance
for treatment interventions and disease etiology and progression, the lack of a clear mechanism in this
body of work does not make it insignificant. It is important to rule out potential biological mechanisms
that could explain health disparities before jumping to social explanations as the cause. In this case,
WMH did not explain the disparate Aβ42 to connectivity relationships we observed in this cohort, and
thus it will be appropriate to explore other biological mechanisms and social constructs, (i.e. cytokines144
or perceived stress124) that exhibit disparities along racial lines.
It is difficult to transpose the findings from this analysis onto our previous results. This analysis
was conducted in a separate, smaller cohort. We detected less significant race X biomarker interaction
terms than our previous analyses. This is likely because this analysis is underpowered, and we did not
have any AA individuals with AD in this cohort, which makes this particular sample non-representative
of the AA with dementia population at-large. The lack of significant findings in this cohort should not be
taken as evidence that WMH do not play a role in DMN connectivity, rather that our sample size was
likely insufficient to detect a significant result, as previous studies with larger sample sizes have identified
relationships between WMH and DMN connectivity in the context of AD4,213,214. An alternative
explanation could be that WMH within the regions that we analyzed may not influence connectivity, and
that other regions outside the DMN subnetworks may be influencing connectivity.
We conducted power analysis to determine how many people we would need to detect a
significant effect given the effect size of our interaction terms. Using the “pwr” package in R. we
determined that we would need a sample size of 118 to detect a significant effect, and our sample size of
66 falls short of this number. We are currently obtaining images from a larger set of both AA and NHW
individuals with NC that also have FLAIR and fMRI data, and we plan to mine the large OASIS dataset
that includes both cross sectional and longitudinal FLAIR and fMRI data of over 700 individuals, with
more than 100 who self-identify as African American215.
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3.5 Chapter 3 tables
Table 4 Results from the replication analyses in the cohort for which we obtained regional WMH
volume. N= 66. dmPFC = dorsomedial prefrontal cortex, PCC = precuneus and posterior cingulate, TC =
lateral temporal cortex, TempP = temporal pole.
B
t
p
dmPFC Race X
-0.002
-2.02
0.05
to PCC CSF Aβ42
Race X
0.004
0.88
0.39
CSF tau
Race X
-0.03
-1.29
0.2
Cognition
LTC to Race X
-0.0001
-0.2
0.84
PCC
CSF Aβ42
Race X
-0.003
-0.74
0.5
CSF tau
Race X
-0.02
-1.5
0.15
Cognition
TemP to Race X
-0.001
-0.5
0.62
PCC
CSF Aβ42
Race X
0.001
0.3
0.77
CSF tau
Race X
-0.02
-1.6
0.11
Cognition
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Abstract
Background: Pathologic and functional studies of Alzheimer’s disease (AD) indicate frontoputaminal networks as sources of neurological changes in response to disease. However, limited research
has examined AD-associated changes in connectivity between the putamen and its supra- and infratentorial outputs, and of their relationships with measures of ischemic injury. In this study, we set out to
determine how functional connectivity between the anterior putamen (APu) and other brain regions
relates to AD and regional white matter hyperintensity (WMH) volume. Because we previously identified
disparate default mode network connectivity patterns between Black/African American (AA) and nonHispanic white (NHW) individuals according to AD, we also analyzed the impact of race on putamenrelated connectivity.
Methods: In our sample of 267 individuals with normal cognition, mild cognitive impairment,
and AD dementia, we measured functional connectivity between APu and multiple cortical regions. We
then modeled the relationships between AD-associated features (cognition, CSF AD biomarker levels),
regional WMH, APu-connectivity, and race.
Results: Measures of AD (diagnosis, worse cognition, and decreased CSF Aβ42) were associated
with increased connectivity between the APu and pre-/post- central gyrus in both races. At the same time,
race modified the relationship between connectivity and measures of AD between the APu and
superior/middle frontal gyri. Frontal and putaminal WMH also had more negative impact on the
connectivity between APu and superior/middle frontal gyri in AA, even though WMH in the same
regions had the opposite effects in NHW.
Discussion: In this manuscript we argue three points: 1) AD alters connectivity between APu and
its input (pre/post central gyrus) independent of race, 2) these changes extend to the superior and middle
frontal gyrus in AAs, and 3) biomarkers of AD and WMH each exerted race-dependent influence on APu
connectivity with the superior/middle frontal gyrus.
Impact statement: This is the first study to specifically probe the APu-related connectivity
according to AD and regional WMH volume. Similar to our prior observations in the default mode
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network, APu connectivity to other brain regions is sensitive to race in some paths, yet independent of
race in others. These extend our previous finding that AD and vascular biomarkers are associated with
differential – and sometimes opposite – functional consequences in AA and NHW.
Acronyms: APu= anterior putamen, NC= normal cognition, AD= Alzheimer’s Disease, WMH=
White matter hyperintensities, AA= African American, NHW= non-Hispanic white, DMN = Default
mode network
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4.1 Introduction
While often overlooked in studies of Alzheimer’s disease (AD) research – including histological
studies, PET, and structural neuroimaging – has shown the putamen and frontal lobe to be vulnerable to
AD pathology as well as ischemic damage. The striatum, which includes the caudate and putamen, may
exhibit amyloid deposition and AD-related atrophy as much as 10 years before symptom onset in
individuals at risk for AD154, 215,216. Similarly, neuritic plaques as well as neurofibrillary tangles begin to
appear in the frontal lobe in early and intermediate stages of AD217,218. The appearance of these pathologic
lesions in AD has further been linked to neuronal dysfunctions through FDG-PET studies219,171,220,221 and
MRI volumetric analysis77with the putamen much more affected by AD than the functionally-related and
spatially adjacent caudate. Therefore, an improved understanding of the putamen’s role in aging and
early AD can provide a novel region for biomarker development and a potential target for clinical
intervention studies.
Functional connectivity is a widely used method for understanding disease related neurological
changes. Functional connectivity is defined as a measure of the synchronicity of blood-oxygen level
dependent (BOLD) signal between brain regions, typically collected during a resting-state functional
magnetic resonance imaging scan 222. Within AD, the most studied regions lie within the default mode
network (DMN) 223. There exist scientific rationale and precedent for examining the impact of AD on
DMN 224, yet other local and large-scale brain connections are often overlooked 223. The functional
networks of the putamen are well-defined in neuroscience due to their importance in movement regulation
and disease. Within the frontal lobe, the putamen is most structurally connected to the superior and
middle frontal gyri, and pre and post central gyri86,126,108,225. These areas are thought to work together to
meet visual spatial and motor demands226,227. The anterior putamen (APu) is classically viewed as a an
associative region while the posterior putamen supports motor function 87. The APu is also more affected
by AD than its posterior counterpart in structural MRI88–90 and better correlates with cognitive decline91.
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Because putamen’s connectivity with other brain regions is also most consistent across individuals among
basal ganglia structures86, the APu is a logical focus of our investigation in AD.
Consistent with this, limited evidence exists to implicate frontal-APu connectivity in AD228–230,
but the opposite has also been reported231. One caveat may be the presence of striatal – more specifically,
putaminal – white matter hyperintensity (WMH) which is commonly observed in older individuals
including those with AD 232. WMH has been linked to strokes and cerebrovascular risk factors (e.g.,
diabetes), 93 but also neuro-inflammation 233. While there is agreement that total brain WMH volume is a
risk factor for AD but is not a specific marker for AD, 234, it remains controversial whether WMH has
uniform etiology or impact on cognition across the brain. Region-specific WMH quantification
implicates vascular disease to associate with amyloid deposition for posterior portion of periventricular
WMH changes 94. However, recent evidence indicates that WMH could emerge independently of
vascular disease and arise as a direct inflammatory response to neuritic plaques in AD103,235.
Relevant to our APu connectivity analysis, WMH can disrupt BOLD synchronicity between
brain regions 236. Decoupling of functional and structural connectivity increases as WMH burden
increases on a global 236 and tract-specific scale108. In AD, regions of the DMN show decreased
connectivity if the WM tracts connecting them have a high WMH burden166. Furthermore, WMH load in
one WM tract can affect functional connectivity between nodes along a separate tract, suggesting direct
and indirect impact on functional connections118. Regional distribution differences in WMH may generate
unique functional network and therefore cognitive profiles that cannot be parsed apart by using total
WMH volume. WMH typically correlate with tests of speed and executive function, and not with tests of
fluid or crystallized intelligence102,237. This suggests that their presence may disrupt intracerebral brain
connectivity, as tests of executive function rely on a coordinated effort of multiple brain regions to
perform tasks 238. Due to their vascular origin and role in brain connectivity, regional WMH differences
may explain many of the functional connectivity changes observed in aging and dementia.
Like other AD biomarker studies, brain network analysis should examine potential differences
between racial groups to test generalizability. Independent of whether self-reported race reflects genetic
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similarity according to region of ancestry, identification with an ethno-cultural group, or structural racism,
there are real and observable biological outcomes from racial disparities which need to be measured 200.
This is particularly true for studies of AD as African Americans (AA) are approximately twice as likely to
develop AD in their lifetime as non-Hispanic whites (NHW), and are more likely to have existing
comorbidities such as vascular disease and type-2 diabetes121,239,240. In keeping with AD biomarker
differences between races, our previous DMN analysis showed disparate relationships between functional
connectivity and AD biomarkers according to race 211. Specifically, AA individuals exhibited increased
connectivity between two tau-related DMN subsystems as disease burden increased. CSF studies have
also shown African American individuals exhibit a unique tau – but not amyloid or neurofilament light
chain – biomarker profiles15,241. Given the complexity between AD, WMH, and race, here we present a
study of APu connectivity in AA and NHW participants using three diverse cohorts recruited from the
Atlanta area.
4.2 Methods
Data collection for all studies, including re-analysis of existing data were approved by the Emory
University and Georgia State University Institutional review board.
Participants
Our analyses consisted of three cohorts of previously collected data from three studies. Separate
tables for each cohort are included in the supplemental materials. Cohorts 1 and 2 (N=66 and 113; PI: Hu)
recruited individuals over the age of 65 including individuals with normal cognition (NC), mild cognitive
impairment (MCI), and AD dementia. Cohort 3 (N=88, PI Wharton) was designed as a study of
cardiovascular risk factors for dementia among African American women with normal cognition. Each
participant underwent a detailed interview for demographic information, self-reported race (Caucasians of
Hispanic or Latino ethnicity were not included in this study), vascular risk factors (coronary artery
disease, congestive heart failure, atrial fibrillation, hypertension, hyperlipidemia, diabetes, suspected
transient ischemic attack), other medical comorbidities (e.g., cancer), and medications (e.g., use of
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angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers). Each participant was then
assigned a diagnosis according to consensus criteria including those for NC, MCI, and AD dementia
(global Clinical Dementia Rating of 1 or 2.) Cognitively impaired subjects suspected of having a non-AD
dementia (vascular, Lewy body, and frontotemporal dementia) were excluded.
For Cohort 3, middle-aged African American and Caucasian subjects were recruited into a study
of cognitively normal subjects with a family history of AD dementia. Demographic (age, sex, education),
diagnostic (syndrome, global Clinical Dementia Rating [CDR], Mini-Mental State Examination [MMSE])
and APOE allelic information were collected. Table 1 includes the demographic information across
cohorts, and table 2 includes demographic information stratified by cohort. Total number of individuals
with NC=187, MCI=53, AD=27.
MRI data collection
All participants were scanned on a Siemens 3T MRI machine at the Emory Center for Systems
Imaging with scanning protocols for each cohort included below.
Cohort 1
Scanning protocol included a T1-weighted 3D MPRAGE sequence (TR/TI/TE =
2400/1060/2.31msec, flip angle = 8o, matrix =320x300, and voxel size = 0.8×0.8×0.8mm3) and a 6 minute
eyes-open resting state functional MRI scan (TR/TE = 724ms/32ms flip angle = 52o, field of view
(FOV) = 220 × 220 mm2, acquisition matrix = 104 × 104, voxel size = 2 × 2 × 2 mm3, slice = 91, time
point = 550), and a T2-weighted Fluid attenuated inversion recovery (FLAIR) can (TR/TI/TE =
9000/2500/91 msec, flip angle = 150o, matrix =256x256, and voxel size = 0.8×0.8x5mm3).s
Cohort 2
Scanning protocol included a T1-weighted 3D MPRAGE sequence (TR/TI/TE =
1620/950/3msec, flip angle = 30o, matrix = 192×256×160, and voxel size = 0.98×0.98×1mm3) and a 6
minute eyes-open resting state functional MRI scan (TR/TE = 3000ms/32ms flip angle = 90o, field of
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view (FOV) = 200 × 200 mm2, acquisition matrix = 64 × 64, voxel size = 3.1 × 3.1 × 3.5 mm3, slice = 33,
time point = 124).
Cohort 3
Scanning protocol included a T1-weighted 3D MPRAGE sequence (TR/TI/TE =
2300/800/2.89msec flip angle = 8o, matrix =256 x256x176, and voxel size = 1×1×1mm3) and a 4.25
minute eyes-open resting state functional MRI scan (TR/TE = 3000ms/32ms flip angle = 90o, field of
view (FOV) = 200 × 200 mm2, acquisition matrix = 220 × 220 x 144, voxel size = 2 x 2 x 2 mm3,
slice = 48, time point = 170).
MRI Data preprocessing
We conducted preprocessing pipelines with identical procedures for each cohort. To control for
the difference in scanning parameters, we included cohort as a fixed effect in our statistical models. We
utilized a standard preprocessing pipeline utilizing the DPARSFA toolbox 172. The first 10 timepoints
were removed, scans were slice time corrected, manually re-oriented, realigned, normalized and smoothed
using the DARTEL & algorithm 213. This algorithm is more appropriate than standard normalization to
the MNI template for special populations, such as those with atrophy. We then performed nuisance
covariate regression (Friston’s 24 parameter head motion regressors, CSF, WM). We further removed
motion-confounds using ICA-AROMA 242 and applied a high pass filter.
Neuropsychological testing
Each cohort utilized a different cognitive battery or test. Data collection for cohort 1 utilized a
cognitive battery as previously described 15. Briefly, this battery included memory tests (Consortium to
Establish A Registry for Alzheimer’s Disease word list delayed recall, Brief Visual Memory Test–
Revised [BVMT-R] delayed recall), (2) executive function tests (Trail Making Test B, reverse digit span
[RD], Symbol Digit Substitution Test, and letter-guided fluency), (3) language tests (Boston Naming Test
[60 items], category fluency), and (4) visuospatial function tests (Judgment of Line Orientation[JOLO],
Rey-Osterrieth complex figure test). With the exception of BVMT-R, JOLO, and RD, subtest Z-scores
were calculated according to published normative data, adjusting for age, sex, education, and race. Z-
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scores for the four domains were averaged to generate composite cognitive Z-scores. Neuropsychological
data collection for cohort 2 included administration of the Montreal Cognitive assessment (MoCA). Data
collection for cohort 3 included administration of the mini-mental state exam (MMSE). To control for the
variety of scales and neuropsychological assessments between cohorts, we z-scored the data from cohorts
2 and 3 according to race, and controlled for cohort in our statistical analysis. In out statistical analyses,
cognitive scores were multiplied by negative one so that an increasing score indicates declining cognitive
performance.
CSF collection
CSF (20 mL) was collected using protocols modified from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) using 24G Sprotte atraumatic needles and syringe between 8AM and
noon without overnight fasting, and transferred into two 15 mL polypropylene tubes. For the Emory
cohort 3, CSF was centrifuged at 2,000 rpm for cellular studies; the supernatant was removed,
immediately aliquoted (500 μL), labelled, and frozen (−80 °C) until analysis. Because CSF-tau is
typically lower in African Americans 243, and tau related changes typically emerge after amyloid
deposition (low CSF Aβ42) 244, we z scored CSF t-tau according to race, and only analyzed CSF t-tau
within individuals with an amyloid z-score of less than 1. We multiplied CSF Aβ42 by -1 so that
increasing amyloid levels indicate increasing amyloid burden.
Area deprivation index
To control for socioeconomic status, we utilized the online neighborhood atlas developed at the
University of Wisconsin, Madison (https://www.neighborhoodatlas.medicine.wisc.edu/). Using
participant addresses, we obtained area deprivation index scores.
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Seed Based Analysis
Using the Wake Forest University Pickatlas v3.0.5, we created
an anterior and posterior putamen mask by creating a 9mm sphere
around the center of the APu, and center of the posterior putamen in
MNI space using coordinates outlined by Oberhuber et al., 2013, for
each hemisphere (Yin et al., 2009. Frontal regions highly connected to
the putamen, as determined by human tractography studies, include the
superior frontal gyrus, precentral gyrus, middle frontal gyrus,
postcentral gyrus (Cacciola et al., 2017). Additionally, the putamen is a
highly lateralized region with strong ipsilateral connections (Cacciola et
al., 2017). As such, we only considered connectivity values between
ipsilateral nodes.
We calculated seed to seed functional connectivity using the
DPARSF-A toolbox. Using our own anterior and posterior putamen
seeds and masks of the aforementioned regions as defined by the
Automated Anatomical labeling atlas, we calculated connectivity
between the putamen and these regions ( Table 3).

Figure 7 Cross sectional images
of the empirically defined anterior
and posterior putamen seeds.
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Figure 8 Visual representation of the connectivity measures used in this analysis. Supplemental
figures include a 3-D representation of the seed maps.

Regional white matter hyperintensity volumes
Total WMH volumes were derived from T2-weighted fluid-attenuated inversion recovery images
software developed by researchers in the Brickman Lab at Columbia University 214. Briefly, each
participant's fluid-attenuated inversion recovery image was corrected for intensity normalization, then
skull-stripped and intensity normalized again. The skull-stripped images were sent through a high pass
filter at the mode of the distribution of the image voxel intensity values. A half Gaussian mixture model
was fit to the log-transformed histogram of the intensity values of each image. The Gaussian distribution
that encapsulated the highest intensity values defined the hyperintense voxels and was labeled. Any
cluster of labeled voxels that comprised fewer than five voxels was removed from the mask. The labeled
images were visually inspected and false positives removed. The number of labeled voxels was summed
and multiplied by voxel dimensions to yield a total volume in cm3. We obtained FLAIR data from
individuals in Cohort 1 and performed this analysis on these 66 individuals.
Regional WMH load
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Because we had many people that did not have a WMH in either the putamen or frontal nodes,
rather than analyze the continuous volumes, we created scores that reflected whether a WMH volume was
present in a particular region. To create regional WMH load, we coded volumes as 0 for not present in
either the putamen or nodes in the analysis (pre and post central gyrus 1 for present in either putamen or
sensorimotor nodes, and 2 for present in both putamen and sensorimotor nodes. We created a similar
score using the same procedure for frontal nodes including the middle and superior frontal gyrus.
Statistical analysis
Anterior putamen connectivity and Alzheimer’s Disease Burden
Diagnostic categories
We created two multivariate linear regression models (one for each hemisphere) that included the
8 pairwise measures of connectivity as dependent variables, self-reported race, gender, cohort, presence
of hypertension and type-2 diabetes, and APOE ε4 carrier status as fixed factors, and age, area deprivation
index, and mean frame-wise displacement as covariates. Diagnostic category was included as a fixed
factor. We corrected for multiple comparisons using the Holm FWER correction method.
AD biomarkers
Next, we analyzed whether AD related biomarkers corresponded with observed connectivity
changes. To further determine which disease biomarkers may be related to connectivity, we constructed
models that did not include diagnosis, and instead included CSF t-tau, CSF Aβ42, cognitive scores, and
putamen-frontal WMH scores, with the same covariates. We corrected for multiple comparisons using the
Holm FWER correction method. To maintain consistency in presentation of our results, cognitive scores
and CSF Aβ42 were inversed such that in our analyses and results, an increasing cognitive score indicates
worse cognitive performance (greater cognitive impairment), and increasing CSF Aβ42 indicates
increasing amyloid burden (lower CSF Aβ42).
Racial differences in frontal to anterior putamen connectivity
Racial differences in normal cognition
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To establish underlying racial differences, we constructed two multivariate linear regression
models (one for each hemisphere) that included the 8 pairwise measures of connectivity as dependent
variables, self-reported race, gender, cohort, APOE ε4 carrier status, and presence of hypertension and
type-2 diabetes as fixed factors, and age, area deprivation index, and mean frame-wise displacement as
covariates. We corrected for multiple comparisons using the Holm FWER correction method. To
maintain consistency in presentation of our results, cognitive scores and CSF Aβ42 were inversed such
that in our analyses and results, an increasing cognitive score indicates worse cognitive performance
(greater cognitive impairment), and increasing CSF Aβ42 indicates increasing amyloid burden (lower
CSF Aβ42).
White matter hyperintensities and connectivity
We next wanted to establish whether there were regional differences between NHWs and AAs in
individuals with mild cognitive impairment within and between the nodes of our fronto-putamen network,
basal ganglia, and the default mode network. We did this using two methods; 1) Performed a chi-squared
test to determine whether the distribution of WMH fronto-putamen scores was different according to race
2) created a multivariate linear regression model that controlled for age, gender, and APOE ε4 status, and
hypertension to determine whether WMH volume was significantly different between races within
individuals with normal cognition.
We also wanted to determine whether CSF Aβ42 was related to putamen frontal WMH load. In
this linear model, CSF Aβ42 was the outcome variable. We controlled for age, gender, race, APOE ε4,
and hypertension.
Racial Differences in AD burden to connectivity relationships
We next analyzed whether race modified biomarkers to connectivity relationships by constructing
two linear mixed models that included diagnosis, CSF t-tau, CSF Aβ42, cognitive z-scores, and putamen
frontal WMH scores and the following interaction terms: race X diagnosis, race X CSF t-Tau, race X CSF
Aβ42 burden, Race X Cognitive impairment, and race X fronto-putamen WMH load. We included the 8
pairwise measures of connectivity as dependent variables, self-reported race, gender, cohort, APOE ε4
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carrier status, and presence of hypertension and type-2 diabetes as fixed factors, with age, area
deprivation index, and mean frame-wise displacement as covariates. We corrected for multiple
comparisons using the Holm FWER correction method. To maintain consistency in presentation of our
results, cognitive scores and CSF amyloid were inversed such that in our analyses and results, an
increasing cognitive score indicates worse cognitive performance (greater cognitive impairment), and
increasing CSF Aβ42 indicates increasing amyloid burden (lower CSF Aβ42).
4.3 Results
Regions of interest
We initially included separate ipsilateral nodes between the APu and the posterior putamen,
caudate, insula, precentral gyrus, postcentral gyrus, middle frontal gyrus, and superior frontal gyrus, as
these regions are the most structurally connected to the putamen (Cacciola, et. al, 2017). In our initial
analyses, cognition and diagnosis were not significantly related to connectivity between the APu and the
posterior putamen, caudate, and insula, and exhibited no racial differences in individuals with NC. Thus,
we report here our analyses for connectivity measures between Apu and the following regions; pre and
post central gyri, and middle and superior frontal gyri for the remainder of the results.
APu connectivity and AD features
Diagnostic categories
After controlling for age, sex, race, and APOE ε4, connectivity between the right APu and the
right precentral gyrus was significantly different among diagnostic categories (precentral: β=0.13,
t(7,255)=1.65, p=0.05; postcentral: β=0.14, t(2,255)=1.79, p=0.05). Individuals with AD had significantly
greater connectivity than individuals with NC and MCI between the right APu and the right precentral.
(Table 3)
Cognitive impairment
Connectivity between the right APu and pre and post central gyrus correlated with cognitive
impairment such that as amyloid burden increased, connectivity also increased (pre-central gyrus: β=0.04,
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t(6,251)=1.70, p=0.04; postcentral gyrus: β=0.05, t(6,251)=2.21, p=0.03) (Figure 3A). There was no such
finding in the left hemisphere. (Table 3)
CSF biomarkers
Connectivity between the left APu and cortical regions correlated with Aβ42 burden (precentral
gyrus: β=0.05, t(6,174)= 1.76, p=0.04; postcentral gyrus: β=0.05, t(6,174)= 1.68, p=0.05) (Figure 3B).
CSF t-Tau was not significantly related to any of our connectivity measures of interest. Model results are
included in the appendix.
Regional WMH load
WMH load within pre and post central gyri and putamen was related to connectivity between
the right and left APu and the respective pre and post central gyri. In the right hemisphere, as WMH load
increased, precentral (β=-0.16, t(6,55)=-2.02, p=0.04) and postcentral(β=-0.18, t(6.55)=-2.43, p=0.01)
gyrus connectivity decreased, and in the left hemisphere, precentral (β=0.09, t(6,55)=2.04, p=0.04) gyrus
connectivity increased (Figure 3D). Neither Regional WMH load was significantly related to CSF Aβ42,
and when CSF Aβ42 was included in the WMH models, beta coefficients for functional connectivity
values did not significantly change. Model results are included in the appendix.
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Figure 9 Race independent connectivity to biomarker relationships. A) Amyloid and functional
connectivity in the left hemisphere between the Apu and the pre and post central gyri.. Line color
indicates region. B) Amyloid burden and functional connectivity in the right hemisphere between the Apu
and pre and post central gyri. Line color indicates region. C) Regional WMH load and functional
connectivity in the left hemisphere in cohort 2. Line color indicates region. D) Regional WMH load and
functional connectivity in cohort 1 in the right hemisphere. Line color indicates region. Grey background
indicates a 95% CI. E) Summary figure of race independent relationships. AA = African American, NC =
normal cognition, WMH= white matter hyperintensities.

65
Racial differences in putamen connectivity
Racial differences in individuals with normal cognition
Within controls, African Americans had significantly lower connectivity than NHWs between the
left APu and the left superior frontal (β=0.11, t(5,177)=2.10, p=0.04), left precentral gyrus (β=0.14,
t(5,177)=2.31, p=0.02), left middle frontal gyrus(β=0.14, t(5,177)=2.79, p=0.01). In the right hemisphere,
African Americans had significantly lower connectivity than NHWs between the right APu and the right
middle frontal (β=0.16, t(6,167)=2.60, p=0.01), and right superior frontal(β=0.15, t(6,167)=2.54, p=0.01).
The presence of type-2 diabetes, and hypertension, and area deprivation index scores did not account for
the effect of race on connectivity. Model results are included in table 3.
Racial differences in amyloid beta and fronto-putamen connectivity
Race significantly modified the relationship between Aβ42 and connectivity between the left APu
and left middle frontal gyrus (β=-0.12, t(7, 172)=-2.25, p=0.02), and the between the right APu and right
middle frontal gyrus (β=-0.20, t(7,172)=-3.30, p=0.001) and the right superior frontal gyrus (β=-0.16,
t(7,172)= -2.36, p=0.02) such that within African Americans, as amyloid burden increased, connectivity
decreased (Figure 4A). Model results are included in the supplemental table.
Racial differences in regional WMH load and functional connectivity
Race significantly modified the relationship between WMH load in the putamen, superior frontal,
and middle frontal gyri and connectivity between the left APu and superior frontal gyrus (β=0.18,
t(6,55)=2.34, p=0.02), and middle frontal gyrus (β=0.16, t(6,55)=1.98, =0.04) (Figure 4B). Model results
are included in the supplemental table.
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Figure 100 Race dependent connectivity to biomarker relationships. A) Amyloid burden and
functional connectivity in the left hemisphere between the Apu and superior and middle frontal gyri. Line
color indicates region. Dashed line indicates race, solid line indicates NHW. B) Amyloid burden and
functional connectivity in the right hemisphere between the Apu and superior and middle frontal gyri.
Solid line indicates African American, dashed line indicates NHW. Grey background indicates a 95% CI.
C) Regional WMH load in the left hemisphere between the middle and superior frontal gyri. Line colors
indicates regions, Solid line indicates African American, dashed line indicates NHW. D) Regional WMH
load in the right hemisphere between the middle and superior frontal gyri. Line colors indicates regions,
Solid line indicates African American, dashed line indicates NHW. E) Summary figure of race dependent
relationships. AA = African American, NC = normal cognition, WMH= white matter hyperintensities.
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4.4 Discussion
In this study, we found that fronto-putaminal functional connectivity is independently associated
with AD and WMH. Connectivity between APu and its cortical inputs (pre-/post-central gyrus) were
related to clinical and biochemical markers of AD. Effects of AD further extended to connections linking
APu with its cortical outputs (superior/middle frontal gyrus) only in African Americans, with opposite
relationships between WMH and connectivity in these regions between African Americans and NHWs.
These findings are consistent with our previous report that African Americans and NHWs may show
opposite patterns of brain connectivity change in parts of the brain but not others.
Prior studies have highlighted altered white matter track integrity between the putamen and its
cortical inputs (post and pre central gyri) or outputs (middle and superior frontal gyri) (Purves, D et al.,
2001) in dementia. Within vascular dementia, the putamen exhibits atrophy and impaired white matter
tract integrity 232. In early stages of AD (e.g., subjective cognitive complaints and mild cognitive
impairment stages), the putamen and frontal lobe also exhibit impaired white matter integrity which
correlates with increased amyloid burden101,248 and decreased regional cerebral blood flow 249. One may
thus expect APu-related connectivity to decrease over time, consistent with current models of decreased
DMN connectivity in AD66,150 211. However, DMN connectivity includes both long and short range brain
connections and is a conglomeration of multiple white matter tracts 250. If networks simplify in the
presence of disease, connectivity between nodes may actually increase198. Indeed, we previously
observed increased connectivity in certain parts of the DMN among African Americans with AD 211. In
the current work, increased connectivity between the APu and pre/post-central gyrus with more
pathologic CSF Aβ42 for both races may also exemplify this phenomenon. Thus we do not interpret this
increase in cortical input to APu as strictly pathological or compensatory at this time. It is therefore not
straightforward to reconcile our findings with white matter tract analysis.
We also used a novel method to quantify WMH in the APu and its cortical connections impacted
in AD. WMH is found commonly in AD and vascular dementia, and their presence in those with vascular
risk factors but no neurological symptoms further complicates their interpretation in
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neurodegeneration102,103,251. A region-specific approach to WMH analysis may better identify the
pathologic process in that anatomical context, but regional analysis has broadly included qualitative or
semi-quantitative distinction between deep vs peri-ventricular, anterior vs posterior, cortical vs.
subcortical, and lobar vs. Brodmann area102,250. Building on the APu connectome, we were able to
directly test whether WMH at APu network nodes influenced the inter-nodal connectivity within and
across individuals. In this case, a negative association between nodal WMH and inter-nodal connectivity
(e.g., right Apu-pre/post-central gyrus) supports the pathological role of nodal WMH, but a lack of
association (e.g., right APu-superior/middle frontal gyrus) does not rule out the importance of WM tract
abnormality. Importantly, the distinct effects of greater plaque burden (more pathologic CSF Aβ42) and
WMH on all but one APu-related connectivity examined do not suggest WMH in the APu network to
reflect AD-related pathology, even if posterior peri-ventricular WMH has been found to more associate
with AD pathology than anterior peri-ventricular WMH.
APu-superior/middle frontal gyrus connectivity was the one measure which differed between
African Americans and NHW. The left APu-cortical connectivity also showed the same direction of
change between AD and WMH in African Americans. Although our analyses did not reveal a
mechanistic explanation for the underlying connectivity differences, as connectivity values were not
related to hypertension, presence of type-2 diabetes, or socioeconomic status, the magnitude and
consistency of regions across hemispheres in which African Americans exhibited lower connectivity
should not be discounted. Potential explanations of the underlying connectivity differences include
dietary and lifestyle habits, brain-specific inflammatory responses 146, environmental and other exposure
associated with poverty
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and stress associated with social and racial inequity 207. In animal and human

neuroimaging studies, stress does seem to exert regional influence on fronto-striatal circuitry, particularly
the middle and superior frontal gyri253–255. The stress of perceived racism, and additional relevant
biological and environmental disparities that exist within the African American population could
predispose these regions to AD pathology, but more research on life stressors would be necessary to draw
this conclusion126,256. It is well recognized that standard predictors of disease progression such as
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cognitive function and hippocampal volumes fall short in determining the rates of cognitive decline in
African Americans113. Limited multi-racial studies have suggested WMH to better track dementia
progression in African Americans than in NHW113, yet many studies continue to exclude individuals with
vascular disease or under-recruit minorities including African Americans. This study reiterates the
importance of including individuals with vascular disease in AD research, especially those with greater
prevalence of vascular disease as well as greater incidence of dementia.
This study has a number of limitations. We recruited more participants with NC and MCI than
AD dementia, thus focusing our work on brain changes in older individuals without severe impairment at
the expense of generalizability. Future research with increased AD dementia participants as well as
longitudinal changes in WMH and AD pathology is necessary to validate the patterns we described. The
cognitive measures utilized were not consistent across cohorts. Although Z-transformation controlling for
cohort effect did yield significant connectivity-to-cognition relationships, casting a more extensive
neuropsychological battery across all cohorts would extend the region-specific analysis to also cognitive
functions. Amyloid and tau PET imaging was not performed in these subjects. Even though CSF Aβ42
levels closely correlate with global amyloid PET measures, the latter may provide higher resolution
characterization of AD pathology in a region-specific manner257.
Conclusion
In this study, we intended to determine whether AD affected putaminal connectivity. We
identified the pre and post central gyrus within a network vulnerable to AD independent of race, and the
superior and middle frontal gyrus within a related network displaying race-specific associations with AD.
Connectivity was increased or showed no change in AD among NHW participants, but decreased more
often than increased in African Americans.
These findings along with our previous work highlight that functional connectivity, like other
intermediate measures of neurodegeneration, is not a linear metric of AD pathology or WMH. It provides
a dynamic profile of neurodegeneration, and region- and context-specific changes likely have pathologic
correlates which need more detailed confirmation. AD pathology appears to have a more consistent
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connectivity profile between APu and its cortical inputs across races, with AD and WMH demonstrating
different patterns of interaction between older African American and NHW participants. This work is in
line with previous research recommendations that considering amyloid, tau, or cognitive decline without
WMH is insufficient for a functional profile of older individuals, yet treating WMH as a uniform measure
of either AD or vascular disease according to qualitative divisions (e.g., anterior vs. posterior) likely
undermines its pathologic significance. Future experimental studies should focus on elucidating
pathologic substrates which can selectively increase or decrease connectivity involving that region, and
connectivity measures in these areas simultaneously vulnerable to AD, vascular injury, and neuroinflammation can then be used to identify the WMH etiologies.
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4.5

Chapter 4 Tables

Table 5 Combined demographic variables for all participants across cohorts. SD = standard deviation. M= male,
F= female. MCI = mild cognitive impairment, AD = Alzheimer’s disease.

Age
mean(SD)
Gender
%M/%F
National
Area
Deprivation
Index
mean(SD)
State Area
Deprivation
Index
mean(SD)
Hypertension
% have
Type-2
Diabetes %
have
Cognitive Z
score
Mean (SD)

Normal Cognition
(N=187)
AA (n=95)
NHW
(n=92)
62.96 (9.29) 65.65 (9.15)

MCI (N=53)

AD (N=27)

AA (n=27)

NHW (n=26)

AA (n=8)

69.38 (7.88)

72.06 (6.36)

21.05/78.95

45.65/54.35

44.44/55.56

46.15/53.85

70.13
(10.34)
37.50/62.50

50.83
(24.10)

33.12
(21.99)

51.69
(23.18)

32.12
(20.73)

59.83
(32.08)

35.38 (21.71)

4.40 (2.56)

2.85 (2.10)

4.38 (2.53)

2.28 (1.49)

5.67 (3.27)

2.94 (1.73)

50.53

34.78

77.78

57.69

75.00

31.58

10.53

4.35

22.22

15.38

25.00

21.05

0.05 (0.92)

0.14 (0.81)

-0.66 (0.58)

-0.87 (0.80)

-2.26 (1.12)

-2.26 (0.70)

NHW
(n=19)
68.86 (8.63)
47.37/52.63
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Table 6 Demographics stratified by cohort. AA = African American, NHW = Non-Hispanic White, SD =
Standard Deviation.
Cohort 1 (N=66)
AA (n=24)
Age
mean(SD)
Gender
%M/%F
National
Area
Deprivation
Index
mean(SD)
State Area
Deprivation
Index
mean(SD)
Hypertension
% with it
Type-2
Diabetes %
with it
Cognitive Z
score
Mean (SD)

Cohort 2 (N=113)
AA (n=52)

69.27
(7.82)
25.00/75.00

NHW
(n=42)
70.03
(6.57)
45.24/54.76

47.83
(23.85)

Cohort 3 (N=88)
AA (n=54)

58.49
(8.34)
15.09/84.91

NHW
(n=36)
58.58
(6.55)
50.00/50.00

27.95
(19.25)

53.19
(21.17)

37.11
(23.19)

51.35
(27.47)

34.65 (21.79)

4.13 (2.52)

2.26 (1.43)

4.60 (2.24)

3.22 (2.26)

4.48 (2.97)

2.82 (2.04)

62.50

30.95

43.40

33.33

69.81

47.46

20.83

7.14

3.77

0

20.75

15.25

-0.06 (1.15)

-0.08 (1.02)

0.07 (0.99)

0.02 (1.02)

-0.66 (0.94)

-0.87 (1.18)

68.92
(7.68)
39.62/60.38

NHW
(n=59)
71.00 (7.87)
44.07/55.93
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Table 7 Coefficients for diagnosis, cognition, and racial differences and connectivity between the
left and right anterior putamen and other regions of interest.
Left Anterior Putamen

Precentral
Gyrus
Postcentral
Gyrus
Superior
Frontal
Gyrus
Middle
Frontal
Gyrus
Posterior
Putamen
Caudate
Insula

B

Cognition
t
p

B

Lower in AA with
NC
t
p

0.42

0.13

1.65

0.05

0.13

2.28

0.02

-0.78

0.43

0.14

1.79

0.05

0.06

1.05

0.29

-0.05

-0.25

0.8

-0.03

-1.43

0.15

0.1

2.09

0.03

-0.12

-0.56

0.58

-0.01

-0.58

0.56

0.14

2.81

0.01

0.12
0.18
0.07

0.56
0.09
0.34

0.57
0.93
0.73

0
0
-0.02

0.03
0.05
-1.01

0.98
0.96
0.31

0.04
0.02
0.08

0.8
0.04
1.52

0.43
0.66
0.13

B

Diagnosis
t
p

-0.07

-0.81

-0.07

Right Anterior Putamen
Diagnosis

Precentral
Gyrus
Postcentr
al Gyrus
Superior
Frontal
Gyrus
Middle
Frontal
Gyrus
Posterior
Putamen
Caudate
Insula

B

t

0.13

1.65

0.14

1.79

-0.07

-0.31

-0.12

-0.64

0.11

0.47

-0.21

-0.93

0.1

0.45

p
0.0
5
0.0
5
0.7
6
0.5
2
0.6
4
0.3
5

Lower in AA with
NC

Cognition
B

t

p

B

t

p

0.04

1.7

0.04

0.07

1.23

0.22

0.05

2.21

0.03

0.06

1.09

0.28

-0.02

-1.39

0.16

0.12

2.27

0.02

-0.02

-1.02

0.31

0.13

2.3

0.02

-0.01

-0.66

0.51

-0.01

-0.11

0.91

0

-0.36

0.72

0.05

0.96

0.34

-1.22

0.22

0.04

0.91

0.36

0
.66 -0.02
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5

CONCLUSION

In the following sections we integrate our findings across aims. We first introduce our research questions
and a summary of related findings. We then discuss findings that are not dependent on race within the
DMN and the putamen and integrate these findings across networks. This is followed by a discussion of
race dependent findings in both the DMN and cortical output putamen nodes, and how these biomarker to
connectivity relationships inform our understanding of AD within AAs. We then review the role, or lack
thereof, of WMH in explaining these relationships, and review other potential explanations for our
findings. We conclude with a discussion of race and how this study answers, but also poses a variety of
questions related to how we should operationalize race in future research.
5.1 Research Questions
The following section includes our research questions as well as a summary of the findings for
each question.
Do African Americans have different connectivity to AD biomarker relationships than NHWs
within the DMN and its subnetworks?
African Americans exhibit a connectivity profile different from that of NHWs. Contrary to NHW
models, precuneus and posterior cingulate connectivity to regions of the dorsomedial subsystem
increases as disease burden increases.
Does putaminal connectivity relate to AD biomarkers?
Connectivity between cortical inputs and the anterior putamen correlates with Alzheimer’s
disease burden such that as CSF Aβ42 decreased, connectivity between the anterior putamen and
pre and post central gyri increased. In the right hemisphere, as cognitive performance decreased,
connectivity increased in these same regions.
Does race modify these relationships between putaminal connectivity and AD biomarkers?
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In the data from the African American participants, as CSF Aβ42 decreased, connectivity
between the anterior putamen and the superior and middle frontal gyri also decreased.
Do hyperintensities in the DMN and in the putamen networks explain the observed racial
differences?
In our sample, hyperintensities in the DMN did not explain the significant race X Aβ42
interaction for DMN connectivity, and did not account for the racial group differences in
connectivity that we observed between APu and superior and middle frontal connectivity.
However, regional hyperintensities within the putamen and these cortical output regions was
related to connectivity in the left hemisphere in African Americans, such that as regional WMH
burden increased, connectivity also decreased.
5.2 Integrating race independent connectivity associations with AD biomarkers
We identified a number of regions for which the relationships between connectivity and AD
biomarkers were consistent across racial groups. In the DMN, these measures include connectivity
between regions of the medial temporal lobe subsystem and between the midline core and medial
temporal subsystems such that as CSF t-Tau increased, connectivity also increased. Within the putamen
network, the consistent measures include connectivity between the anterior putamen and the pre and post
central gyri. Within these regions, as disease burden (measured by the particular biomarker) increased,
connectivity also increased. Typically individuals with a higher AD burden exhibit lower connectivity
between DMN regions, but results are inconsistent in the putamen64,258. The increased connectivity that
we observed within the DMN may be driven by the relatively larger group of individuals with MCI
compared to AD. Because an increase in connectivity is often observed in MCI59, and many studies
consider diagnostic categories instead of continuous biomarker measures, and only a few studies have
examined DMN subnetworks in AD259,260, our results may not directly map onto previous studies.
However, because the DMN subnetworks have unique functions measures (i.e. MTL correlates with
memory and midline core is responsible for self-reflection)62, and do not exhibit uniform relationships
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with biomarkers as observed in the first aim, we recommend utilizing these subnetworks in future studies
investigating DMN connectivity and continuous relationships with biomarkers.
Connectivity between the anterior putamen and its cortical input nodes (pre-post central gyrus)
were related to both cognition and amyloid. The hyperconnectivity that we observed could be a
pathological response to disease presence, or functional compensation as other regions begin to succumb
the effect of AD. These particular measures of connectivity were independent of race, and thus we would
recommend them as ROI’s in future studies in diverse cohort. If others achieve replication of our results
within this network, we could then recommend that this network be a preferred network of study in
samples with diverse of individuals across the disease spectrum of AD. A previous EEG study identified
hyperexcitability in the presence of AD within the sensorimotor cortex261, despite the fact that this region
is relatively spared from atrophy. This finding highlights an advantage of functional connectivity
approaches, as it can examine complex neurological interactions beyond cell death. A summary figure of
the race independent relationships is included below.

Figure 111 Summary figure of general race independent relationships between increasing disease
burden as measured by AD biomarkers. Green line indicates the DMN MTL functional connectivity.
Yellow indicates pre and post central gyri connectivity. DMN MTL = Default mode network medial
temporal lobe, APu = anterior putamen.

This works gives partial support to the amyloid hypothesis in that it is initial amyloid deposition
that starts the dementia cascade. The DMN, the first network to be affected in the course of AD was

77
related to both CSF tau and amyloid58. However, the putamen and its cortical nodes were not related to
tau, but more consistently related to amyloid. According to Braak staging, the frontal lobe is affected later
in the course of disease199. The amyloid hypothesis states that amyloid build up causes a metabolic
cascade that eventually leads to tau deposition, but precedes NFT’s by many years24. Atrophy typically
correlates more strongly with tau, as the NFTs are what may trigger cell death. Amyloid buildup may
signal the first stages of AD, and generate some of the functional changes that can be observed in fMRI
studies. The consistent amyloid relationships that we identified in the putamen analyses could also reflect
the overall impact of amyloid even in normal aging, as amyloid plaques are fairly common even in
individuals with intact cognition. Further research would benefit from amyloid PET262 studies that
identify whether regional amyloid buildup in the putamen network we describe relates to connectivity.
The fact that tau was related to DMN MTL connectivity, but not to fronto-putaminal connectivity
is in line with previous literature168. We would likely see significant relationships between tau and
connectivity in a larger set of individuals in the later stages of dementia. Amyloid emerges earlier, and
our cohort did have early MCI and individuals with NC. Based on Braak staging, frontal regions are not
typically inundated with tau until later in the disease199, and our cohort did have a larger proportion of
controls. It is likely that some of these individuals had amyloid deposition, but had not, or will never cross
the threshold into the Braak stages of tau deposition in the frontal areas. Further tau-pet45 studies of
individuals with MCI and AD should investigate these regions to determine if regional tau deposition may
correlate with connectivity in the putamen nodes that we identified.
We identified relationships with cognition and connectivity in both of our networks of interest.
Although related inversely to connectivity within NHWs for our DMN measures, it is important to
recognize that connectivity measures were related to cognition in Cohort 3, which included individuals
across the dementia spectrum, including AAs with AD, and related to a variety of connectivity within the
DMN between the midline core and dorsomedial subsystems. Within the putamen network, cognition
correlated with connectivity measures in the right hemisphere, between the right anterior putamen and the
right pre and post central gyri. The lack of many significant relationships between cognition and
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connectivity identified between the putamen and network regions could be a result of the fact that our
sample for the putamen connectivity analyses included a larger group of individuals who were younger
and had normal cognition. Our findings could indicate that amyloid exerts greater influence on
connectivity without much relationship to cognition in this putamen network particularly earlier in the
stages of AD or eventual AD153. Before cognitive symptoms emerge, amyloid could exert influence on
connectivity, in a variety of regions including the putamen and its cortical nodes, but connectivity in these
regions may not exhibit relationships with cognition and tau until much later in the disease263. An
alternative explanation could be that the cognitive tests utilized in these cohorts are better at detecting
memory impairment than impairment in other cognitive domains. The cognitive scores utilized in the first
aim were taken from an extensive cognitive battery, but the other cohorts only had the MMSE and the
MoCA. While the MoCA is more sensitive to cognitive domains for which the putamen and the cortical
nodes are responsible (motor and visual spatial impairment)52, utilizing a different cognitive measure for
each cohort likely introduces noise that obfuscates relationships between cognition and putamen
connectivity, especially given the cultural bias associated with these assessments that often over-predicts
cognitive impairment in African Americans264. Future studies will investigate individuals with MCI and
AD to determine whether putamen connectivity does indeed exhibit relationships with tau and cognition
and whether these alterations manifest in cognitive performance, and investigate the relationships
between cognitive domains outside of memory and the relationship to putamen connectivity.
5.3 Race Dependent relationships with AD biomarkers
Current consensus drawn from functional, structural, and pathological studies is that the
hippocampus and the DMN are the primary regions affected by Alzheimer’s Disease59. While research of
these areas has yielded a wealth of scientific findings with clinical utility, there are many questions about
the etiology and disparities within AD that may be answered by broadening the scope beyond the DMN
and hippocampus. The DMN has been thoroughly explored in AD, and results across studies with similar
definitions of the DMN, and similar methodological approaches have fairly consistent findings indicating
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that DMN within network connectivity is lower in individuals with AD compared to NC, and declines as
the disease progresses59. This work adds to the current body of literature by replicating previous studies
and that use the DMN subnetwork connectivity measures in our sample of NHWs, and providing
measures that may be sensitive to the biological changes generated by diverse ethno-cultural
backgrounds.
Our findings within the NHW sample support previous literature that, within this group, DMN
connectivity typically declines as AD burden increases. Our data-driven ICA approach to identifying
components of the DMN, rather than utilizing seed-maps, could have been responsible for the increases
we observed in AA, in that our data driven component maps perhaps did not represent the established
DMN regions. However, because we identified the typical pattern of AD-related connectivity decline in
NHWs, we can be fairly certain our methodology choice does not account for the disparate connectivity
to biomarker relationships that we observed.

African Americans are less likely to exhibit amnestic profiles than their NHW counterparts; they
have slower cognitive and functional decline, and different predictors of cognition. These facts
compounded with evidence for a unique functional profile point to a possible sub classification of
Alzheimer’s disease that includes a consideration of lifestyle and genetic risk factors. Some papers
suggest that MCI is characterized by a temporary increase in DMN connectivity, followed by the gradual
decline associated with AD. AAs in our sample could be exhibiting an extended MCI-like connectivity
profile. The diagnosis of AD within AA could be generated by a lower level of pathology, yet is
exacerbated by comorbidities such as vascular disease. This may seem counter intuitive, but it suggests
contributing comorbidities extant in AAs cause AD symptoms to emerge with a much lower pathology
burden than in NHWs. This also may contribute to their greater life expectancy as the AA phenotype of
AD may not be as severe, and may be more attributable to other neurological burdens. These results
would be in line with other studies that have identified slower rates of cognitive decline in African
Americans109, and these connectivity increases could be an extension of this MCI hyperconnected phase.
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Further studies investigating a greater number of AA individuals with AD would be necessary to explore
this hypothesis.
In Alzheimer’s disease, the hippocampus is typically included in default mode network analyses155.
The DMN supports self-referential cognitive processes, including memory. Lower functional connectivity
between DMN regions typically correlates with worse general cognition, higher AD burden, and worse
memory performance63. Our findings from the first aim provide a neurological basis for the increased
prevalence of non-amnestic MCI in African Americans and possibly explain why cognitive decline tends
to progress more slowly in African Americans. Cognitive assessments tend to rely heavily on working
memory265. The MMSE and MoCA both include at last one question that relies on memory, and lower
working memory capabilities can impair assessment performance even on questions designed to assess
visuospatial abilities. MoCA is more sensitive to detecting cognitive impairment other than memory, but
both of these assessments are most commonly used to detect Alzheimer’s disease265. Cognitive tasks that
specifically assess motor function may be more sensitive to AD detection in African Americans as a result
of underlying vulnerable region.
African Americans exhibited decreased connectivity between the APu and superior and middle
frontal gyrus as CSF Aβ42 decreased. It is possible that the hyperconnectivity between the cortical input
regions and the APu that we observed is a form of functional compensation for connectivity decline in
other brain regions. We observed a decline in connectivity between DMN nodes in NHWs as AD burden
increases, and between APu and superior and middle frontal in AAs (Figure 11). In individuals with
normal cognition, African Americans exhibited lower connectivity between the anterior putamen and the
superior and middle frontal gyrus. This finding, coupled with the increase in connectivity between the
putamen and the pre and post central gyrus across races suggests that while there are uniform
relationships between AD pathology and motor-putamen circuits, downstream frontal regions may be
preferentially affected by race.
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Figure 122 summary figure of race dependent relationships between increasing disease burden as
measured by AD biomarkers. Only relationships within African Americans are displayed in this figure.
Green line indicates the DMN MTL functional connectivity. Yellow indicates pre and post central gyri
connectivity. DMN MTL = Default mode network medial temporal lobe, APu = anterior putamen.

We were not able to identify any variables that fully accounted the differences in biomarkers
across racial groups. Many of the variables typically entangled with race, such as socio-economic status,
hypertension, and white matter hyperintensity volume did not account for the effect of race on the
biomarker to connectivity relationships in the DMN or in the putamen. Explanations for our findings
could be a result of a complex interplay of biological and sociological factors whose measurement was
outside the scope of this study. African Americans in these samples on average had lower socioeconomic
status as measured by the ADI. However, including ADI in our analyses did not account for the
significance of interaction terms. It is possible the ADI serves as a crude measure of SES, as it is merely a
snapshot of where an individual resides at a particular time, and that is not the only factor entangled with
race that may explain these racial differences. Low socio-economic-status266 and perceived racial
discrimination, both commonly reported in AAs205, can affect the brain throughout the developmental
spectrum. These factors create decreased connectivity across large scale brain networks that could create
reliance on small scale networks267, and these connections would then be reinforced over time. This could
create a functional connectome that relies heavily on a functionally segregated, rather than integrated,
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networks. Resilience to negative outcomes associated with challenging life events is associated with
increased connectivity between the sensorimotor cortex and the putamen, a phenomenon that we observed
in both races, though unrelated to resilience268. The slow decline observed in African Americans could be
a result of the fact that previous reliance on small scale networks would be less impacted by Alzheimer’s
disease than NHWs, and that our NHW cohort exhibits functional integration that declines in response to
disease. This could explain the slow decline exhibited by African Americans, as the networks would
already be organized into functionally segregated networks, and the presence of disease may just enhance
this underlying network structure. However, in NHWs in our sample, cognitive function would be
primarily reliant on functional integration, and a disruption in this integration caused by AD pathology
would lead to segregation and force networks to reorganize at a more rapid pace. A graph theoretical
approach, particularly of longitudinal data, would allow us to test these hypotheses.
5.4 WMH and DMN connectivity
Our hypothesis that regional WMH within the DMN explained the significant effect of race on
connectivity and biomarker relationships was not supported. WMH within these regions were not related
to connectivity, and did not account for the significant race interaction term. However, this finding is not
conclusive, and warrants further exploration in a larger dataset. Our cohort that included the connectivity
and WMH data was not the same cohort used for our Aim 1 analyses. There were less participants in the
WMH dataset, and we did not identify identical relationships between biomarkers and connectivity within
this dataset. This is likely that we were underpowered to detect an effect, and that our cohorts had a
different diagnostic distribution. In our WMH analysis dataset, we did not have any AAs with AD, only
NC and MCI, but we did have NHWs across all diagnostic categories. Furthermore, the cognitive data
from this cohort was limited to one general measure of cognition rather than from a battery of
neuropsychological tests.
We did not identify regional differences between AA and NHW in WMH volume within the
tracts of the DMN regions that we investigated. These DMN subsystem WMH volumes were not related
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to CSF Aβ42 or CSF T-tau, even when we only utilized data from individuals with MCI and AD. If we
did identify a significant relationship between CSF biomarkers and regional WMH volume, it would
support the notion that WMH in these regions may be caused by AD pathology. However, our results do
not support this hypothesis. Our findings are not conclusive, as we had a relatively small sample size (23
individuals with some form of cognitive impairment), and of those individuals, only 10 had
corresponding CSF data. It is likely that we were underpowered, and a larger sample size would be
necessary to detect a significant relationship between WMH and CSF biomarkers, especially given the
differences in CSF T-tau levels between NHW and AAs.
WMH within the default mode subnetworks did not mediate the race by biomarker interaction
terms. This finding should not be taken as conclusive evidence that WMH do not play a role in DMN
connectivity. We were not able to replicate same race and biomarker interactions that we identified in the
cohort of our first aim. This is likely a result of the limited distribution of our sample across race and
diagnostic categories. However, previous studies do support these findings. Studies have inconsistently
identified a relationship between amyloid and WMH, and between tau and WMH99,102,269. Many of the
studies that correlate tau with WMH do so at a pathological post-mortem level, and identify WMH based
on pathology rather than MR imaging. Little research exists that probes the mechanistic relationship
between tau and WMH, and without longitudinal models, it will be difficult to establish a causal
relationship. However, as tau-pet becomes more widely used, answering this question will become more
feasible.
5.5 WMH and Putamen Connectivity
This work illustrates the importance of considering not only racial groups in analyses of
individuals with AD, but comorbidities. Ruling out individuals who have contributing comorbidities may
be appropriate to generate models that specifically study mechanisms related only to AD, but if other
comorbidities are in fact risk factors for the disease being studies270, the synergistic mechanisms between
the disease of study and the comorbidities will be largely ignored. This research emphasizes the important
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role of the contributing factors of vascular insult in the form of small vessel disease, as represented by the
presence of WMH in the brain. Because we identified WMH burden in many controls in the absence of
elevated amyloid beta, WMH may be generated ahead of amyloid burden, and not directly caused by ad
pathology. This WMH does play a role in decreasing basal ganglia function particularly in AAs, which
manifests as lower mid and superior connectivity. It is likely that in fronto-putamen regions, WMH
increases susceptibility to the effects of Aβ42, rather than Aβ42 generating WMH. This finding adds to
the hypothesis that AD related WMH are located in more posterior and temporal regions101 rather than
frontal and subcortical WMH, which seem to be more vascular in nature271. This work also adds to the
hypotheses that WMH can disrupt pathways not only along tracts, but also within nodes65. Current
research is limited to tract specific findings, but this work demonstrates that nodal WMH can also
influence functional connectivity, particularly in metabolically active areas sensitive to oxygen and
nutrient deficits.
The putamen and thalamus are regions particularly vulnerable to ischemic changes272. Metabolic
studies indicate that these regions are highly metabolically active. This increased metabolic activity would
make them particularly susceptible to the oxygen and nutrient deficits generated by ischemia and small
vessel disease273. However, it is not likely that putamen WMH are the cause of the connectivity
relationships we identified as being related to AD. In this work, we identified what regions exhibit
connectivity changes related to AD, and those related to WMH. These two factors likely have a
synergistic effect on connectivity, with African Americans exhibiting greater susceptibility to WMH.
Why AAs exhibit this vulnerability remains unclear.
The current work supports the notion that amyloid burden is not related to WMH etiology. Within
the amyloid literature, the relationship between WMH and amyloid is also controversial. The evidence
that amyloid and WMH have a causal relationship is weak, and many studies have found no relationship
between the two biomarkers even across different modalities of amyloid measurement (amyloid pet,
amyloid staining, and CSF amyloid).
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5.6 Limitations & Future Directions
Our findings should be considered in context of this work’s limitations. We did not have uniform
measures across all participants. Our cognitive measures were different across the three cohorts, and we
did not have regional WMH for all participants. We were able to identify consistent relationships between
connectivity and cognition across the cohort despite this limitation, but the extensive cognitive battery
with standardized scores as we have for cohort 2 would obviously provide more accurate measures of
cognition that would not exhibit the racial bias evident in more general tests of cognition. The lack of AA
individuals with AD in the WMH limits the generalizability and validity of our findings such that we
cannot fully overlay our functional relationships identified in Aim 1 on our WMH results. Future analyses
will explore regional WMH and connectivity in a larger cohort with particular emphasis on a larger
number of AA individuals with AD.
Our analyses were limited to studying race and biomarker interaction terms, and considering the
effects of gender were outside the scope of this study. In addition to race, gender also has biological and
social definitions. Disparities exist between genders such that women are more likely to develop AD274,
but live longer than men with AD. Studying the impact of intersectionality in Alzheimer’s Disease can
widen the net of individuals with whom clinicians should consider at risk for AD and allow for more
targeted public health campaigns and interventions to address some of the modifiable factors of AD that
may be entangled with these social and biological categories.
Although we were able to include a large percentage of AA individuals across our cohorts, we did
not have a sufficient number of AA individuals with AD to completely replicate our findings from Aim 1.
While we did identify some consistent relationships across cohorts in cohort 1, a larger sample of AA
individuals with AD would be ideal to determine the generalizability of our results. While this work does
establish biological manifestations of health disparities, there are a number of biological and sociological
factors that we did not consider that may play a role in the manifestation of these disparities. As
previously mentioned, the sociological aspects of race, while socially constructed in nature, can generate
disparate health outcomes. For example, perceived racial discrimination205, lower socio-economic
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status275, education quality276, and residential environment during childhood252, family and community
bonds, and resilience277, all of which show differences across racial groups, can have negative and
protective effects on brain health. Our sample of African Americans should in no way be taken as
representative of all African Americans. A nuanced approach of examining the aforementioned variables
should be the focus of future analyses, rather than broad categorization of individuals based on race.
However, in order to increase participation of individuals of diverse in science studies and make the case
for national investment of funds in this effort, establishing gross racial differences is the first step.
The only measures of pathology that we used were derived from CSF. While this is useful in
determining the validity of our connectivity measures and whether they are related to gross levels of CSF
tau and amyloid, it would be valuable to investigate the regional distribution of tau and amyloid through
PET scans, and whether regional distribution of these pathologies are related to connectivity and regional
WMH. This would enable us to more accurately add to the WMH etiology debate, and determine how
these pathologies may affect connectivity, i.e. are tau and Aβ42 within the DMN generating functional
connectivity changes, or is the DMN responding to amyloid and tau deposition elsewhere is the brain.
This study used cross-sectional data across the disease spectrum to understand how biomarkers
and connectivity are related to one another at varying levels of disease burden. However, to uncover
casual mechanisms and develop disease trajectories that may be specific to a particular race, longitudinal
models would be necessary. We modeled the biomarker and connectivity relationships using linear
functions, as that is the simplest and most logical place to begin an analysis. However, our understanding
of how CSF biomarkers change over the course of the disease is limited, particularly within African
Americans. The relationship between CSF Aβ42 and connectivity could be stronger in the earlier phases
of the disease, and then plateau as the amyloid threshold for the development of AD is reached37. While
this can be modeled in a cross sectional analysis, a longitudinal analysis would provide more sensitivity to
track changes across disease development, and we can adjust current disease trajectory models to include
race, and introduce regional staging of functional connectivity changes. We would also like to confirm
that WMH emerge before functional connectivity changes using a longitudinal model, and whether CSF
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tau and amyloid alterations in the CSF occur before the emergence of WMH. While it seems logical that
WMH could influence FC, we are still not sure whether the two variables are correlated or causally
related. It also seems logical that WMH would be present before CSF and tau alterations, but that is under
the assumption that WMH are not caused by AD pathology278. While this study suggests that WMH are
independent of AD pathology, a longitudinal analysis would provide more conclusive evidence either
way.
This work brings into question the definition of race. Many people try to define race as a purely
genetic concept193, but the lines between races from a purely genetic standpoint are nonexistent in the US
at least. In fact, many NHWs in the U.S. exhibit similar genetic profiles to AAs279. This leads others to
argue that race is purely a social construct with little biological utility11. The answer most likely lies
somewhere in the middle, as this work can attest to. A failing of this work is that we have had to include
African Americans as one group, when in fact “African Americans” are a diverse minority group with a
variety of socioeconomic, genetic, and lifestyle backgrounds. The term “African American” obviously
has some utility in the clinic, as African Americans do have higher prevalence rates of AD1. However,
when we controlled for many of the factors that could potentially explain the racial disparities that we
identified, such as presence of vascular disease, type-2 diabetes, socio-economic status, and risk genes,
we still had significant racial differences that no variable fully explained. This work supports the notion
that “race” in the context of Alzheimer’s Disease is more of a complex interplay between ethnicity,
ancestry, and lifestyles, and that “ethno-cultural” group may more accurately describe the African
American diaspora280. Furthermore, cohort effects may impact our results, as many of the older
individuals in our studies grew up in a time of racial turmoil during or just after the conclusion of the civil
rights movement276. While the current time leaves much to be desired in the area of race relations, the
level of institutional racism present during the time of segregation and just after could create a lingering
impression on brain health that cannot be captured by merely examining biological and lifestyle factors276.
While we have to establish meaningful differences in order to encourage the inclusion of a diverse cohort
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in future studies, we hope that in the future, more nuanced and precision approaches to quantifying ethnocultural backgrounds can be adopted.
As this work conclusively shows, characterizing the functional profile of individuals with
Alzheimer’s disease must be an inclusive process. A one-brain-fits-all approach doesn’t address the
unique differences between sample populations. Even structural templates vary based on sample
population, let alone functional connectomes with a larger number of variables. While we identified
regions that did exhibit the same biomarker to connectivity patterns across races a number of these
measures, particularly in the network most commonly studied in AD, we must carefully choose our
regions of interest, and consider the makeup of our sample accordingly. Putamen input nodes seem to be
consistently related to amyloid across races, while DMN connectivity should be considered with race as a
variable of interest for analyses in cohorts that include African Americans and NHWs. If functional data
is to be used as a biomarker for early detection of AD, or to predict conversion from MCI to AD, we must
strive to create a profile that includes not just individuals from all backgrounds, but individuals who at the
greatest risk of developing the disease.
.
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